




Washington, DC • September 7-9, 2012

IMAGINE ...


PROGRAM



...WHERE WE
COULD BE IN
THE NEXT
10 YEARS

Welcome to the Celebration of Science

As Will Durant famously noted, “The health of nations is more important than the wealth of nations.” Wealth follows health. More than half of economic growth in the past century is attributable to advances in the biosciences, where investments provide long-term benefits through increased productivity, job creation, lower healthcare costs and cheaper energy. More important, bioscience has given millions of people worldwide the incalculable gifts of longer lives, less suffering, greater hope and more time with loved ones. That’s worth celebrating.



This weekend marks the second time we’ve brought a group to Washington in support of a greater national commitment to bioscience. Fourteen years ago this month, the March on Washington united hundreds of thousands of patients, families, doctors and advocates on the Mall. In the years following the 1998 March, Congress greatly expanded the resources of the National Institutes of Health, the National Cancer Institute and the National Science Foundation.

Those investments have driven extraordinary progress, and we’re now at the dawn of a new scientific revolution that will not only reduce the cost of health care but will save, extend and improve the quality of people’s lives across the planet. Science and technology advances have transformed the impossible into the routine; processes that once took years and cost millions now can be performed quickly and inexpensively. As just one important example, the original sequencing of the human genome took 13 years and cost \$3 billion; today it’s approaching two hours and \$1,000.

As impressive and transformative as those advances have been, they’re merely a prologue to the next decade. Throughout this program, you can read the thoughts of distinguished Celebration of Science participants about what that decade might bring. This much is clear: We’ve entered the era of precision medicine, where therapies are customized to treat the complex genetic makeup of the patient instead of attacking disease with blunt force. Surgeons are swapping scalpels for noninvasive technologies that use light, sound and magnetism. Emerging treatments render many forms of cancer impotent, and the dream of an AIDS-free generation is within reach.

That’s why we’ve convened members of Congress, current and past cabinet secretaries, directors of U.S. science agencies, Nobel laureates, university presidents, philanthropists, senior management of many of the nation’s largest employers including pharmaceutical and biotech companies, prominent health economists and 600 leading scientists and clinicians. By assembling such a diverse range of leaders, we hope to forge a uniquely bipartisan consensus about the importance of bioscience.

Thank you for joining us for three days to change the world.

Sincerely,

A handwritten signature in dark ink that reads "Michael Milken". The signature is fluid and cursive, with the first name "Michael" being more prominent than the last name "Milken".

Michael Milken
Chairman
FasterCures



IMAGINE WHAT WE'LL ACCOMPLISH IN BIOSCIENCE IN THE NEXT 10 YEARS

“There’s never been a time where we’ve had a greater outpouring of discoveries about the nature of disease, many of them from basic science, uncovering the molecular causes of both rare and common diseases. If there was ever a time when we all need to get together and figure out how to take this wonderful scientific opportunity and apply the most bold, audacious principles of innovation to make those products happen, it is now.”


FRANCIS COLLINS
M.D., PH.D.

*Director
National Institutes
of Health*

“Your efforts are crucial – not only in making progress against life-threatening diseases, but also in addressing the issues of sustainable energy, clean water, abundant food, pollution abatement and protection from pandemics and bioterrorism.”

GEORGE H.W. BUSH

*41st President of the
United States*



“Stem cells generated from a patient’s own blood and skin samples will allow us to do clinical trials in a dish. We will treat patients with individualized drugs and therapies tailored to their genetic type.”

SUSAN L. SOLOMON


*CEO, The New York Stem
Cell Foundation*



“1) The creation of a medical [Star Trek-like] tricorder that allows consumers to use a hand-held wireless device to diagnose themselves – equal to that of a physician. 2) A vaccine for AIDS. 3) Life detected on the subsurface of Mars. 4) A 10-fold increase in battery power storage densities.”

PETER H. DIAMANDIS, M.D.

*Chairman/CEO, X PRIZE
Foundation*



“1) Non-invasive treatments for cancer, Parkinson’s disease, epilepsy and brain tumors; 2) surgery without incisions or anesthesia; and 3) the means to deliver chemotherapeutics directly to a tumor, avoiding systemic complications.”

NEAL F. KASSELL, M.D.

*Founder and Chairman,
Focused Ultrasound Foundation*

LOOKING

“We know which proteins cause cancer to form, grow, and spread, yet we are unable to stop this process because our current drugs cannot alter their functions. In 10 years, we will overcome this scientific stumbling block and have a profound effect on cancer and health.”

ROBERT DEN, M.D.

Department of Radiation Oncology, Thomas Jefferson University Hospital

“We will be close to having a broadly effective vaccine for HIV.”

MARGARET G. MCGLYNN

*CEO and President,
International AIDS Vaccine Initiative*

“Individuals with paralysis will be able to use artificial limbs using only their thoughts.”

LEIGHTON CHAN, M.D., MPH

*Chief, Rehabilitation Medicine
Department, Clinical Center,
National Institutes of Health*

“The closing decades of the 20th century witnessed a revolution of biomedical research fueled by innovations in molecular biology. This revolution will dominate the first half of the 21st century, aided by new tools, reaching a true, fundamental understanding of the human brain.”

JAY SCHNITZER, M.D., PH.D.

Director, Defense Sciences Office, DARPA

“In 2022, artificial intelligence will have produced a global cloud-based medical intervention system where a simple cheek swab will put an individual into a genetic database at birth, allowing preemptive medical intervention for everyone, regardless of financial or social status.”

GREG HOFFMAN

Prostate Cancer Foundation (Patient/Survivor)

“I envision rapid progress in the movement of cancer from a lethal disease for 50% of its victims to a manageable chronic disease, if not a cure, for all.”

JULIA H. CARTER, PH.D.

President, Wood Hudson Cancer Research Laboratory

FORWARD

→ to future advancements...



“I believe we’ll see a significant reduction in the 15 years it currently takes to move life-saving therapies from discovery to patients. By working together – advocates, foundations, industry, government, academia and investors – with and for patients, we’ll speed up the medical research process and save lives by saving time.”

MARGARET ANDERSON
*Executive Director,
FasterCures*



“We will see the emergence of ‘Magic Johnsons’ of oncology – individuals with previously fatal solid tumors who are able to achieve long-term disease control with excellent quality-of-life.”

**ANDREW J. ARMSTRONG,
M.D., SCM**
*Associate Professor of
Medicine and Surgery,
Duke Cancer Institute*



“We will increasingly define cancer as digital information derived from abnormalities in the genome. Physicians will use Google-like tools to analyze massive amounts of data to develop personalized disease profiles and select specific technologies tailored for the diagnosis and/or treatment of a patient’s specific cancer.”


ANNA D. BARKER, PH.D.
*Arizona State University,
Former Deputy Director,
National Cancer Institute*



“New nanotech and molecular technologies will provide maps of brain circuits and functions, yielding insight into how the brain computes thoughts and emotions, and pointing the way toward new mechanisms for treating intractable brain disorders that affect over a billion people worldwide.”

ED BOYDEN, PH.D.

*Associate Professor,
MIT Media Lab and McGovern Institute, Departments of Biological
Engineering and Brain and Cognitive Sciences*



“A world without blindness is no longer a dream. Gene therapies are restoring vision in blind children. Stem cells are replacing retinal tissue lost to age-related disease. Thanks to science, soon everyone will see.”

GORDON GUND

*Chairman of the Board,
Foundation Fighting Blindness*



“We will be able to screen individuals for cellular changes early in disease, thereby treating on an individual basis before the disease has the ability to progress to a dangerous state.”

ANGELA MOSKOW

*Center for Chronic Disease
Prevention and Wellness,
Sanofi*



“A new TB vaccine that can prevent disease in adolescents and adults.”

KARI STOEVE

*Vice President, External Affairs,
Aeras*

“The future of science lies in mobilizing crowdsourcing to resolve scientific problems. The limitations of the closed research environment can be exponentially expanded by outsourcing innovation from the lab to the crowd as shown by online gamers who achieved a scientific discovery within three weeks after scientists had failed for a decade.”

SHMUEL MEITAR

*Board Member,
Prostate Cancer Foundation*



PROGRAM & ACTIVITIES



CONFERENCE NOTES

Name Badge Identification

You are required to wear your Celebration of Science name badge at all times during the conference for admittance to meals and sessions. The conference badge is not transferable.

Suggested Attire

Friday: Business dress

Saturday/Sunday daytime: Business casual

Saturday night: Cocktail attire

Session Seating

Seating for sessions is first-come, first-served.

Kennedy Center Seating

Tickets will be required for Saturday evening. Attendees should pick up their tickets in front of the Eisenhower Theater.

Registration

Hours of operation at each host hotel:

Friday 7:00 a.m. – 5:00 p.m.

Saturday 6:00 a.m. – 12:00 p.m. and 2:00 p.m. – 5:00 p.m.

Sunday – opens at 6:00 a.m.

Registration will also be available at the offsite venues: GWU, NIH, and all special evening functions.

National Institutes of Health

The National Institutes of Health is a secure campus. At the Natcher Conference Center, you will go through a security screening. Do not bring sharp objects, large knives or weapons to the campus. Please bring a picture ID.

George Washington University

George Washington University is accessible by Metro, taxi or car. The Foggy Bottom GWU Metro stop (on the Blue and Orange lines) at 21st Street and I Street NW is closest to the campus. Parking is available at the Academic Center Garage on I Street between 21st and 22nd Streets or the garage beneath the Marvin Center building at 800 21st Street NW.

Cell Phones and Mobile Devices

As a courtesy to our panelists and guests, please set cell phones and mobile devices to silent mode during the conference.

HOST HOTELS

Four Seasons Hotel

Registration in front of Algonquin Room
2800 Pennsylvania Avenue, NW
Washington, DC 20007

JW Marriott Hotel

Registration in Senate Room
1331 Pennsylvania Avenue, NW
Washington, DC 20004

Mayflower Hotel

Registration on the Promenade
1127 Connecticut Avenue, NW
Washington, DC 20036

ATTENTION: YOU MAY BE RECORDED

The Celebration of Science is being videotaped and/or audio taped for broadcast over the air, on the Internet or otherwise. As a member of the audience, you may be recorded. By attending this program, you grant permission to *FasterCures*/the Milken Institute to use your appearance, likeness and/or voice in connection with any photographing, video/audio taping and/or rebroadcast of the program.

AGENDA

Friday, September 7, 2012 – Private Morning Session

Accelerating Innovation in the Bioscience Revolution

8:00 a.m.

Four Seasons Hotel
Corcoran Ballroom
2800 Pennsylvania Avenue, NW
Washington, DC 20007

A private retreat by invitation only

Friday, September 7, 2012 – Afternoon Panels and Talks | Noon – 5:35 p.m.

George Washington University
Jack Morton Auditorium
805 21st Street, NW (corner 21st and H Street)
Washington, DC, 20052

Seating is very limited. These panels, hosted in a production auditorium, will be recorded for future broadcast. Entry and exit from the auditorium will be possible only during breaks between sessions, and we ask attendees to stay through the end of the afternoon's sessions at 5:35 p.m.

Welcome Remarks

Noon – 12:20 p.m.

Speaker:

» **Steven Knapp**, President, George Washington University

A CELEBRATION OF SCIENCE

Anthony Fauci and Earvin “Magic” Johnson discuss progress against HIV/AIDS 12:20 – 12:45 p.m.

Speakers:

- » **Anthony Fauci**, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- » **Earvin “Magic” Johnson**, Chairman and CEO, Magic Johnson Enterprises

Moderator:

- » **Greg Simon**, CEO, Greg Simon, Inc.; Member, *FasterCures* Board of Directors

Anthony Fauci and Trevor Mundel Discuss Global Health 12:50 – 1:15 p.m.

Speakers:

- » **Anthony Fauci**, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- » **Trevor Mundel**, President, Global Health Program, Bill and Melinda Gates Foundation

Moderator:

- » **Greg Simon**, CEO, Greg Simon, Inc.; Member, *FasterCures* Board of Directors

Your NIH – A 20-Year Perspective 1:20 – 2:10 p.m.

Speakers:

- » **Francis Collins**, Director, National Institutes of Health
- » **Harold Varmus**, Nobel Laureate; Director, National Cancer Institute; former Director, National Institutes of Health
- » **Elias Zerhouni**, President, Global Research and Development, Sanofi; former Director, National Institutes of Health

Moderator:

- » **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

The Interaction of Government, Industry and Academic Centers 2:15 – 2:30 p.m.

Speaker:

- » **Andrew von Eschenbach**, President, Samaritan Health Initiatives Inc.; former Commissioner, U.S. Food and Drug Administration; former Director, National Cancer Institute

RENEWING OUR COMMITMENT TO THE FUTURE

Linking Prevention, Care and Cures

2:35 – 3:25 p.m.

Speakers:

- » **Renzo Canetta**, Vice President, Oncology Global Clinical Research, Bristol-Myers Squibb
- » **Ezekiel Emanuel**, Diane and Robert Levy University Professor, University of Pennsylvania
- » **Lynn Goldman**, Dean, George Washington University School of Public Health and Health Services
- » **Steven Rosenberg**, Chief of Surgery, National Cancer Institute

Moderator:

- » **Risa Lavizzo-Mourey**, President and CEO, Robert Wood Johnson Foundation

Past Achievements and Future Potential in Bioscience

3:30 – 3:45 p.m.

Speaker:

- » **Eric Lander**, President, Broad Institute of Harvard and MIT; Co-Chair, President's Council of Advisors on Science & Technology (PCAST)

The FDA: Past, Present and Future

3:50 – 4:40 p.m.

Speakers:

- » **Margaret Hamburg**, Commissioner, U.S. Food and Drug Administration
- » **Mark McClellan**, Senior Fellow, Director, Engelberg Center for Health Care Reform, Brookings Institution; former Administrator, Centers for Medicare and Medicaid Services
- » **Ellen Sigal**, Chairperson and Founder, Friends of Cancer Research

Moderator:

- » **Margaret Anderson**, Executive Director, *FasterCures*

Accelerating Basic, Translational and Clinical Research

4:45 – 5:35 p.m.

Speakers:

- » **James Greenwood**, President and CEO, Biotechnology Industry Organization
- » **Robert Langer**, Institute Professor, Massachusetts Institute of Technology
- » **John Reed**, CEO, Sanford-Burnham Medical Research Institute
- » **Janet Woodcock**, Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- » **Keith Yamamoto**, Vice Chancellor for Research, UCSF; Executive Vice Dean, School of Medicine; Professor, Cellular and Molecular Pharmacology

Moderator:

- » **Chris Viehbach**, CEO, Sanofi

Friday, September 7, 2012
Reception and Dinner at the National Portrait Gallery

Donald W. Reynolds Center for American Art and Portraiture
Smithsonian National Portrait Gallery
Third Floor Galleries/Kogod Courtyard
Eighth and F Street, NW
Washington, DC 20004

Reception (Third Floor Galleries)

6:00 – 7:30 p.m.

Dinner (Kogod Courtyard)

7:45 – 10:15 p.m.

Host:

» **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

Performers:

» **Melissa Manchester**

» **Stevie Nicks**

Appearances by:

» **Brian Bilbray**, United States Representative, California

» **Peter Chiarelli**, CEO, One Mind for Research; General (ret.), U.S. Army

» **Francis Collins**, Director, National Institutes of Health

» **Peter Diamandis**, Chairman and CEO, X PRIZE Foundation

» **Chaka Fattah**, United States Representative, Pennsylvania

» **Geoff Ling**, Program Manager, Defense Sciences Office, DARPA

» **Jay Schnitzer**, Director, Defense Sciences Office, DARPA

» **Joe Torre**, Executive Vice President, Major League Baseball; Founder, Safe at Home

» **Fred Upton**, United States Representative, Michigan (Chairman, Energy and Commerce Committee)

Saturday, September 8, 2012 – A Day at the NIH

National Institutes of Health
Natcher Conference Center
Bethesda, MD

Please refer to the map in the back of this program.

Host:

Susan Dentzer, Editor-in-Chief, Health Affairs

Welcome

9:30 – 9:40 a.m.

Opening Remarks:

- » **Francis Collins**, Director, National Institutes of Health

The Impact of Biomedical Research on our Health and the Economy

9:40 – 10:10 a.m.

Speakers:

- » **Eric Cantor**, United States Representative, Virginia (Majority Leader)
- » **Francis Collins**, Director, National Institutes of Health
- » **Steny Hoyer**, United States Representative, Maryland (Minority Whip)

Moderator:

- » **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

HIV/AIDS: Yesterday's Progress, Tomorrow's Promise

10:10 – 10:30 a.m.

Speakers:

- » **Moises Agosto**, Director of Treatment Education, Adherence, and Mobilization, National Minority AIDS Council
- » **Dawn Averitt Bridge**, Founder and Chair, The Well Project
- » **Timothy Ray Brown**, "The Berlin Patient"; Founder, The Timothy Ray Brown Foundation of the World AIDS Institute
- » **Sharon Hillier**, Professor, Department of OB/GYN, University of Pittsburgh

Towards an HIV Vaccine - LiveCAM

10:30 – 10:40 a.m.

Speaker:

- » **Peter Kwong**, Chief, Structural Biology Section in the Laboratory of Virology, Dale and Betty Bumpers Vaccine Research Center

Interviewer:

- » **Francis Collins**, Director, National Institutes of Health

A CELEBRATION OF SCIENCE

The Protein Folding Problem

10:40 – 11:00 a.m.

Speaker:

- » **Susan Lindquist**, Member, Whitehead Institute; Professor of Biology, MIT; Investigator of the Howard Hughes Medical Institute

Uncovering the Mystery of the Brain

11:00 – 11:20 a.m.

Speakers:

- » **Judy Bachrach**, Contributing Editor, Vanity Fair
- » **Kafui Dzirasa**, Assistant Professor, Department of Psychiatry and Behavioral Science, Duke University School of Medicine

Using Imaging to Explore our Brains – LiveCAM

11:20 – 11:30 a.m.

Speaker:

- » **Daniel Reich**, Director, Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Interviewer:

- » **Francis Collins**, Director, National Institutes of Health

The NIH Impact on Prevention, Care and Research

11:30 – 12:00 p.m.

Speakers:

- » **Freda Lewis-Hall**, Executive Vice President, Chief Medical Officer, Pfizer Inc.
- » **Jonathan Rothberg**, Founder and CEO, Ion Torrent, Life Technologies Corporation
- » **Elias Zerhouni**, President, Global Research and Development, Sanofi; former Director, National Institutes of Health

Moderator:

- » **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

Lunch

12:00 – 1:20 p.m.

Speakers:

- » **Benjamin Cardin**, United States Senator, Maryland
- » **Chris Van Hollen**, United States Representative, Maryland

RENEWING OUR COMMITMENT TO THE FUTURE

Restoring Mobility and Independence – LiveCAM

1:30 – 1:40 p.m.

Speaker:

- » **Diane Damiano**, Chief, Functional and Applied Biomechanics, Rehabilitation Medicine Department, National Institutes of Health

Interviewer:

- » **Francis Collins**, Director, National Institutes of Health

Research and Rehabilitation of Our Wounded Soldiers

1:40 – 2:00 p.m.

Speakers:

- » **Geoff Ling**, Program Manager, Defense Sciences Office, DARPA
- » **Paul F. Pasquina**, Colonel, U.S. Army Medical Corps, Chief, Department of Orthopedics and Rehabilitation, Walter Reed National Military Medical Center and Director, Center for Rehabilitation Sciences Research, Uniformed Services University of the Health Sciences
- » **Jonathan Pruden**, Captain (ret.), U.S. Army

Precision Medicine

2:00 – 2:20 p.m.

Speakers:

- » **Joe, Retta, Zach, Noah and Alexis Beery**, Whole Genome Sequencing Success Story
- » **Richard Gibbs**, Director, Human Genome Sequencing Center, Wofford Cain Professor of Human and Molecular Genetics, Baylor College of Medicine

Closing Session

2:20 – 2:30 p.m.

Remarks by:

- » **Francis Collins**, Director, National Institutes of Health
- » **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

A CELEBRATION OF SCIENCE

Saturday, September 8, 2012
An Unforgettable Evening at the Kennedy Center

John F. Kennedy Center for the Performing Arts

Eisenhower Theatre, 2700 F Street, NW, Washington, DC

8:00 p.m. – 10:15 p.m.

Hosts

Whoopi Goldberg | John O’Hurley

Performers

Kenny “Babyface” Edmonds | Melissa Manchester | Stevie Nicks | The Genes and Jazz Quintet

Appearances by

Margaret Anderson

Executive Director, *FasterCures*

Robert Beall

President and CEO, Cystic Fibrosis Foundation

Nancy Brinker

Founder and CEO, Susan G. Komen for the Cure; former U.S. Ambassador to Hungary

Deborah Brooks

Co-founder & Exec. Vice Chair, The Michael J. Fox Foundation for Parkinson’s Research

Eric Cantor

United States Representative, Virginia (Majority Leader)

S. Ward Casscells

Tyson Distinguished Prof. of Medicine and Public Health, Univ. of Texas at Houston

Francis Collins

Director, National Institutes of Health

Daniel Inouye

United States Senator, Hawaii (Chairman, Committee on Appropriations)

Story Landis

Director, National Institute of Neurological Disorders and Stroke

Freda Lewis-Hall

Executive Vice President, Chief Medical Officer, Pfizer Inc.

Christopher Logothetis

Chair, Dept. of Genitourinary Medical Oncology, MD Anderson Cancer Center

RENEWING OUR COMMITMENT TO THE FUTURE

Connie Mack III

Former United States Senator, Florida

Michael Milken

Chairman, Milken Institute; Founder, *FasterCures*

Nancy Pelosi

United States Representative, California (Minority Leader)

Harry Reid

United States Senator, Nevada (Majority Leader)

Jonathan Simons

President and CEO, Prostate Cancer Foundation

Rudolph Tanzi

Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School

Harold Varmus

Nobel Laureate; Director, National Cancer Institute

Winter Vinecki

Founder, Team Winter

James Watson

Nobel Laureate; Chancellor Emeritus, Cold Spring Harbor Laboratory

Elias Zerhouni

President, Global R&D, Sanofi; former Director, National Institutes of Health

And many others

Featuring the “Entertainers of Science”

Terry Bishop, Keyboard

John Burklow, Guitar

Francis Collins, Guitar

Wolfram Goessling, Trumpet

Bill Kimmell, Rhythm Guitar

Daniela Krause, Flute

Jonathan Lewin, Alto Sax

Steve Libutti, Drums

Frank Longo, Keyboard

John O’Shea, Guitar / Mandolin / Drums

Sally Rockey, Vocals

Tracey Rouault, Keyboard

Rudolph Tanzi, Keyboard / Harmonica

John Tisdale, Bass

Alan Wayne, Jazz Guitar

Leonard Zon, Trumpet

Musical Director • Glen Roven

Sunday, September 9, 2012 – Panels and Talks | 8:40 a.m. – 12:30 p.m.

George Washington University
Marvin Center
800 21st Street, NW (at H Street)
Washington, DC 20052

Seating is on a space-available basis. These panels, hosted in a production auditorium, will be recorded for future broadcast. Room assignments will be posted at the venue.

**Translation, Innovation and Commercialization:
Role of the NCI's Comprehensive Cancer Centers**

8:40 – 9:30 a.m.

Speakers:

- » **Ronald DePinho**, President, The University of Texas MD Anderson Cancer Center
- » **Stephen Gruber**, Director, USC Norris Comprehensive Cancer Center, University of Southern California
- » **William Nelson**, Director, Kimmel Comprehensive Cancer Center at Johns Hopkins
- » **Steve Rosen**, Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine

Moderator:

- » **Anna Barker**, Director, Arizona State University Transformative Healthcare Networks; Co-director of the Complex Adaptive Systems Initiative; Former Deputy Director, National Cancer Institute

Economic Return on Bioscience Initiatives

8:40 – 9:30 a.m.

Introductory remarks:

- » **Alan Krueger**, Chairman, White House Council of Economic Advisers

Speakers:

- » **Frank Lichtenberg**, Courtney C. Brown Professor of Business, Columbia University Graduate School of Business, and Research Associate, National Bureau of Economic Research
- » **Tomas Philipson**, Senior Fellow, Milken Institute; Daniel Levin Professor of Public Policy Studies, Irving B Harris Graduate School of Public Policy Studies, University of Chicago

Moderator:

- » **Ross DeVol**, Chief Research Officer, Milken Institute

RENEWING OUR COMMITMENT TO THE FUTURE

STEM Education and Job Prospects for Young Investigators

8:40 – 9:30 a.m.

Speakers:

- » **Cora Marrett**, Deputy Director, National Science Foundation
- » **Lesa Mitchell**, Vice President, Innovation and Networks, Ewing Marion Kauffman Foundation
- » **Lorelei Mucci**, Associate Professor, Harvard School of Public Health
- » **Sally Rockey**, Deputy Director for Extramural Research, National Institutes of Health

Moderator:

- » **Steven Knapp**, President, George Washington University

The Prospect of Eradicating AIDS

8:40 – 9:30 a.m.

Speaker:

- » **Anthony Fauci**, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Moderator:

- » **Michael Manganiello**, Founding Partner, HCM Strategists

Bioscience in Energy, Environment, Water, Agriculture, and Bioterror Defense

9:40 – 10:30 a.m.

Speakers:

- » **Steven Chu**, Nobel Laureate; United States Secretary of Energy
- » **Eric Lander**, President, Broad Institute of Harvard and MIT; Co-Chair, President's Council of Advisors on Science & Technology (PCAST)
- » **Subra Suresh**, Director, U.S. National Science Foundation

Moderator:

- » **Jean-Lou Chameau**, President, California Institute of Technology

A CELEBRATION OF SCIENCE

Who Pays for Treatment and Cures?

9:40 – 10:30 a.m.

Speakers:

- » **Gary Gottlieb**, President and CEO, Partners Healthcare
- » **Michael Leavitt**, Founder and Chairman, Leavitt Partners; formerly Environmental Protection Agency Administrator, Secretary of Health and Human Services, and Governor of Utah
- » **Mark McClellan**, Senior Fellow, Director, Engelberg Center for Health Care Reform, Brookings Institution; former Administrator, Centers for Medicare and Medicaid Services

Moderator:

- » **Thomas Priselac**, President and CEO, Cedars-Sinai Health System

The Role and Benefits of Prevention and Wellness Programs

9:40 – 10:30 a.m.

Speakers:

- » **Kent Bradley**, Chief Medical Officer, Safeway
- » **Luigi Fontana**, Research Associate Professor of Medicine and Associate Director, Longevity Research Program, Washington University in St. Louis School of Medicine; Professor of Nutrition, Salerno University Medical School
- » **Joe Fortunato**, Chairman, President and CEO, General Nutrition Centers
- » **Kevin Volpp**, Staff Physician, Philadelphia VA Medical Center; Director, Center for Health Incentives and Behavioral Economics, and Professor of Medicine and Health Care Management, University of Pennsylvania

Moderator:

- » **David Heber**, Professor of Medicine and Public Health; Director, UCLA Center for Human Nutrition, David Geffen School of Medicine, UCLA

Patient Groups and the Drug Discovery Process

9:40 – 10:30 a.m.

Speakers:

- » **Bonnie Addario**, Founder & Chair, President, Bonnie J. Addario Lung Cancer Foundation
- » **Deborah Brooks**, Co-founder and Executive Vice Chairman, The Michael J. Fox Foundation for Parkinson's Research
- » **Peter Chiarelli**, CEO, One Mind for Research; General (ret.), U.S. Army
- » **Susan Solomon**, CEO, The New York Stem Cell Foundation
- » **Mary Woolley**, President and CEO, Research!America

Moderator:

- » **Margaret Anderson**, Executive Director, *FasterCures*

RENEWING OUR COMMITMENT TO THE FUTURE

Leveraging Medical Philanthropy

10:40 – 11:30 a.m.

Speakers:

- » **Leon Black**, Founding Partner, Apollo Management; Co-founder, Melanoma Research Alliance
- » **Gordon Gund**, Co-founder, Foundation Fighting Blindness
- » **David Koch**, Executive Vice President, Koch Industries; Koch Institute for Integrative Cancer Research at MIT
- » **Melissa Stevens**, Deputy Executive Director, *FasterCures*

Moderator:

- » **Michael Milken**, Chairman, Milken Institute; Founder, *FasterCures*

Opportunities and Challenges for Research Universities

10:40 – 11:30 a.m.

Speakers:

- » **Gene Block**, Chancellor, University of California, Los Angeles
- » **John Holdren**, Director, White House Office of Science and Technology Policy; Co-Chair, President's Council of Advisors on Science and Technology (PCAST)
- » **Paul Rothman**, Dean of the Medical Faculty, CEO, Johns Hopkins Medicine
- » **Joel Seligman**, President, University of Rochester

Moderator:

- » **Michael Crow**, President, Arizona State University

The Coming Age of Precision Medicine

10:40 – 11:30 a.m.

Speakers:

- » **Carl June**, Director, Translational Research, Abramson Cancer Center; Richard W. Vague Professor of Immunotherapy, Perelman School of Medicine, University of Pennsylvania
- » **Nathan Price**, Associate Professor, Institute for Systems Biology
- » **Jonathan Rothberg**, CEO, Ion Torrent
- » **Max Wicha**, Distinguished Professor of Oncology; Director, University of Michigan Comprehensive Cancer Center

Moderator:

- » **Andrew von Eschenbach**, President, Samaritan Health Initiatives Inc.; former Commissioner, U.S. Food and Drug Administration; former Director, National Cancer Institute

A CELEBRATION OF SCIENCE

Biological Effects of Physical Energy

10:40 – 11:30 a.m.

Speakers:

- » **Michael Idelchik**, Vice President, Advanced Technologies, GE Global Research
- » **Neal Kassell**, Chairman, Focused Ultrasound Foundation; Professor of Neurosurgery, University of Virginia
- » **Jonathan Lewin**, Chair, Department of Radiology; Professor of Radiology, Oncology, Neurosurgery, and Biomedical Engineering, Johns Hopkins University
- » **Carmen Puliafito**, Dean, Keck School of Medicine, University of Southern California

Moderator:

- » **Roderic Pettigrew**, Director, National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Science and Progress at the FDA

10:40 – 11:30 a.m.

Speakers:

- » **John Lim**, CEO, Health Sciences Authority, Singapore
- » **Eric Perakslis**, Chief Information Officer and Chief Scientist (Informatics), U.S. Food and Drug Administration

Moderator:

- » **Vicki Seyfert-Margolis**, Senior Advisor, Science Innovation and Policy, Office of the Commissioner, U.S. Food and Drug Administration

Advances Against the Crafty Cancer Cell

11:40 – 12:30 p.m.

Speakers:

- » **Tyler Jacks**, Director, David H. Koch Institute for Integrative Cancer Research and Professor of Biology, MIT; Investigator, Howard Hughes Medical Institute
- » **Steven Rosenberg**, Chief, Surgery Branch, National Cancer Institute
- » **Charles Sawyers**, Investigator, Howard Hughes Medical Institute; Chair, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- » **Owen Witte**, Director, Broad Stem Cell Research Center; Investigator, Howard Hughes Medical Institute; Professor, Microbiology and Pharmacology, University of California, Los Angeles

Moderator:

- » **Margaret Foti**, CEO, American Association for Cancer Research

RENEWING OUR COMMITMENT TO THE FUTURE

Alzheimer's and Other Issues of Aging

11:40 – 12:30 p.m.

Speakers:

- » **Jeffrey Cummings**, Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas
- » **Rudolph Tanzi**, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital
- » **George Vradenburg**, Chairman and Co-founder, USAgainstAlzheimer's

Moderator:

- » **Freda Lewis-Hall**, Executive Vice President, Chief Medical Officer, Pfizer Inc.

Investment Opportunities in Medical Research

11:40 – 12:30 p.m.

Speakers:

- » **Margaret Hamburg**, Commissioner, U.S. Food and Drug Administration
- » **Jim Healy**, Managing General Partner, Sofinnova
- » **Jonathan Leff**, Managing Director, Warburg Pincus
- » **Francois Maisonrouge**, Senior Managing Director, Evercore Partners
- » **Dennis Purcell**, Senior Managing Partner, Aisling Capital

Moderator:

- » **Mark Simon**, Advisor, Torrey Partners

A Conversation with Nobel Laureate James Watson

11:40 – 12:30 p.m.

Speaker:

- » **James Watson**, Nobel Laureate; Chancellor Emeritus, Cold Spring Harbor Laboratory

Interviewer:

- » **Jonathan Simons**, President and CEO, Prostate Cancer Foundation



SPEAKERS



BONNIE ADDARIO, an eight-year lung cancer survivor, is founder and chair of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), a San-Francisco-based nonprofit. Prior to founding BJALCF, she was the president of both the Commercial Fueling Network and Olympian Oil Co. In 2007, Addario led the launch of the Addario Lung Cancer Medical Institute, a virtual institute with a shared specimen repository and database with real-time information. The purpose is to serve as an honest, third-party broker so researchers around the world can collaborate and accelerate discovery and raise the standard of care for all patients. She has served as a director of the Sequoia Hospital Foundation Board, vice chair of the University of California, San Francisco Thoracic Cabinet, and an advocate and member of the Southwest Oncology Group Lung Committee. Addario is an active member of the International Association of the Study of Lung Cancer and the American Association for Cancer Research. She is also member of the *FasterCures* initiative TRAIN/The Research Acceleration and Innovation Network.



MOISES AGOSTO is a longtime advocate and educator in the field of HIV/AIDS and currently serves as the director of the treatment education, adherence and mobilization division of the National Minority AIDS Council (NMAC) in Washington, D.C. Prior to his role at NMAC, Agosto was a program manager for the International Treatment Preparedness Coalition (ITPC), a program of the Tides Center, where he was responsible for program and grant-making activities in the Caribbean region, Latin America and East Africa. Before working for ITPC, he was vice president and managing director of Community Access, a company of the Publicis Healthcare Communications Group, served as editor of *SIDAahora* magazine, a publication of the People With AIDS Coalition in New York, and was an active member of ACT UP New York. Additionally, Agosto has served on numerous government, industry and community advisory boards. He resides in San Juan, Puerto Rico.



MARGARET ANDERSON is executive director of *FasterCures/The Center for Accelerating Medical Solutions*, a Milken Institute center that works to speed up the timeline for new medicines to go from discovery to patients. In 2011, the Clinical Research Forum recognized her with an award for leadership in public advocacy. Anderson is the president of the Alliance for a Stronger FDA and served as a board member of the Council for American Medical Innovation and the Coalition for the Advancement of Medical Research. She is also co-chair of the Council on Data and Research and a member of the Institute of Medicine's Forum on Drug Discovery, Development and Translation. Previously Anderson was at the Academy for Educational Development, the Society for Women's Health Research, the American Public Health Association and the Congressional Office of Technology Assessment. She holds a bachelor's degree from the University of Maryland and a master's in science, technology and public policy from George Washington University.

A CELEBRATION OF SCIENCE



JUDY BACHRACH joined Vanity Fair as a contributing editor in 1995. She has profiled a wide range of public figures and produced features on some complicated topics: the decision to place Chile's much-hated former dictator Augusto Pinochet under house arrest near London, the brutal murder of Maurizio Gucci in Italy, and the attempt by a brilliant teenage boy to arrange his own suicide on the Internet (the latter article has been optioned for a film by director Bryan Singer). Prior to joining Vanity Fair, Bachrach was a political columnist with the Washington Star. She began her career as a TV critic at the Baltimore Sun and went on to write for the style section of the Washington Post for five years. Bachrach wrote "Tina and Harry Come to America: Tina Brown, Harry Evans, and the Uses of Power" (Free Press, 2001).



ANNA BARKER is director of Transformative Healthcare Networks at Arizona State University, which fosters new research models to better prevent and treat disease. Until 2010, she was deputy director of the National Cancer Institute (NCI), and deputy director of the institute's Center for Strategic Scientific Initiatives. At NCI she developed and implemented multidisciplinary programs in cancer research, including the Nanotechnology Alliance for Cancer, the Cancer Genome Atlas, the Clinical Proteomics Technologies Initiative for Cancer and a network of physical sciences-oncology centers. She also led the development of resources to enable personalized cancer medicine in bioinformatics through the Cancer Human Biobank; was founding co-chair of the NCI-FDA Interagency Oncology Task Force; and oversaw NCI's international cancer programs. Barker served as a senior scientist and later a senior executive at Battelle Memorial Institute, as well as CEO of a public biotechnology drug development firm she founded before joining the NCI. Barker holds an M.A. and Ph.D. from Ohio State University.



ROBERT BEALL is president and CEO of the Cystic Fibrosis Foundation (CFF), where he has worked for more than 30 years to bring new therapies to patients. In 1988, CFF launched its groundbreaking Therapeutics Development Program, a unique partnership among industry, academics and CFF that fosters new approaches for CF drug discovery and development. As a result, more than 30 potential therapeutic products are currently in the pipeline. Beall previously served on the medical school faculty of Case Western Reserve University and worked at the National Institutes of Health, managing much of the CF program. He received his Ph.D. in biochemistry from the State University of New York at Buffalo.

THE BEERY FAMILY - Joe, Retta and their children Zach, Noah and Alexis - are an example of a whole genome sequencing success story. Twins Noah and Alexis, who were diagnosed as toddlers with dopa-responsive dystonia, became mysteriously ill when they were 12. The mystery illness was solved by whole genome sequencing, which found both had a serotonin deficiency. The 16-year-old twins now appear on such programs as the "Today Show," "Good Morning America" and "NOVA," and at speaking engagements to bring hope to many suffering with rare and undiagnosed ailments. Joe Beery is chief information officer of Life Technologies, Inc. in Carlsbad, Calif. Retta Beery is a patient advocate who runs a website and speaks around the world about the family's experience. Their oldest son, Zach, attends the University of Michigan as a freshman.



BRIAN BILBRAY, a life-long San Diegan, represents the 50th Congressional District in Southern California. He serves on the House Energy and Commerce Committee, a panel with broad legislative oversight regarding communications, consumer protection, energy, environment and health. Bilbray also serves as co-chairman of the House Biomedical Research Caucus and the House Algae Energy Caucus, which promote San Diego's leadership position in the life sciences and clean-technology industries. To encourage growth and job creation in these industries, Bilbray has introduced legislation to help protect the vibrant life sciences community, whose patients' lives depend on innovation, as well as legislation that advances the search for renewable fuels that will one day curb the United States' dependence on foreign oil.



LEON BLACK is managing partner of Apollo Management LP, which he founded in 1990 to manage investment capital for a group of institutional investors, focusing on corporate restructuring, leveraged buyouts and taking minority positions in growth-oriented companies. He is also chairman and CEO of Apollo Global Management, LLC. He is also co-founder of the Melanoma Research Alliance. Previously Black worked at Drexel Burnham Lambert as managing director, head of the Mergers & Acquisitions Group and co-head of the Corporate Finance Department. He serves on the boards of Apollo and Sirius XM Radio Inc., and is a general partner of AP Alternative Assets. Black is also a trustee of The Museum of Modern Art, Mount Sinai Hospital, The Metropolitan Museum of Art and The Asia Society. He is a member of the Council on Foreign Relations and The Partnership for New York City as well as the boards of *FasterCures* and the Port Authority Task Force. He has a bachelor's degree from Dartmouth College and an M.B.A. from Harvard Business School.

A CELEBRATION OF SCIENCE



JAMES BLAIR has been a partner of Domain Associates, LLC, since its founding in 1985. He has been involved in the creation of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, GeneOhm Sciences, NuVasive, Pharmion and Volcano. He sits on the boards of Proteomics, Astute Medical, Cadence Pharmaceuticals, Clovis Oncology, NeuroPace and Zogenix. A former managing director of Rothschild Inc., Blair was involved at a senior level with the company's venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co. From 1961 to 1969, Blair was an engineering manager with RCA Corp., during which time he received a David Sarnoff Fellowship. He serves on the board of the Prostate Cancer Foundation and on the advisory boards of the Department of Molecular Biology at Princeton University, the University of Southern California's Stevens Institute for Innovation, the Caltech Division of Chemistry and Chemical Engineering, and the Caltech Innovation Initiative.



GENE BLOCK is the chancellor of UCLA, where he holds faculty appointments in psychiatry and biobehavioral sciences and in physiological science. Before coming to UCLA, Block was vice president and provost at the University of Virginia. His research has focused on biological timing and the brain mechanisms responsible for circadian rhythms. He was founding director of the NSF Science and Technology Center for Biological Timing. Appointed chancellor in 2007, Block oversees UCLA's three-part mission of education, research and service. He has defined academic excellence, civic engagement, diversity and financial security as priorities for his administration. A champion of public universities, he was recognized for his efforts to increase access for underrepresented students with the Los Angeles NAACP Foundation President's Award in 2009. He is a member of the American Academy of Arts and Sciences and a fellow of the American Association for the Advancement of Science.



BARBARA BOXER is serving her fourth term representing California in the U.S. Senate after 10 years in the House of Representatives. She chairs the Senate Environment and Public Works Committee and the Senate Select Committee on Ethics, and is a senior member of the Senate Commerce Committee and Senate Foreign Relations Committee. A strong proponent of life-saving medical research, Boxer supported doubling funding for the National Institutes of Health and wrote bipartisan legislation to accelerate America's contribution to combat global HIV/AIDS and tuberculosis. In 2010, she founded the Senate Military Family Caucus to help address the challenges faced by families of U.S. service members. She worked to establish the West Coast Combat Care Center in San Diego to treat severely wounded service members. She also helped create the Defense Task Force on Mental Health and secured millions in federal funding to improve medical care for severely burned soldiers.

RENEWING OUR COMMITMENT TO THE FUTURE



KENT BRADLEY is chief medical officer of Safeway, Inc., a Fortune 100 company with more than 170,000 employees. Board-certified in preventive medicine, Bradley is responsible for supporting the company's portfolio of health-care programs, including its employee and consumer wellness and prevention activities. He also assists the Safeway Health, Inc., subsidiary on a range of business initiatives. A graduate of the United States Military Academy, Bradley has a master's degree in public health from the University of Minnesota and an M.B.A. from the University of Denver. He received his medical degree from the Uniformed Services University of Health Sciences.



DAWN AVERITT BRIDGE is the founder and chair of the Well Project, a nonprofit organization formed in 2002 to improve the lives of women living with HIV and AIDS, and the founder of National HIV Awareness Month. After being diagnosed with HIV at age 19, Bridge has become one of the nation's most prominent HIV and AIDS advocates. As the founder of the Women's Research Initiative on HIV/AIDS, she has been instrumental in shifting the research paradigm to include more women and people of color. Bridge also serves on the Presidential Advisory Committee on HIV/AIDS, and her numerous board and panel affiliations range from an FDA advisory panel to several NIH working groups. In 2007, she received a Women Leading Change Award from the World YWCA for her leadership in addressing the HIV and AIDS pandemic.



NANCY BRINKER, a former U.S. ambassador to Hungary, is the founder and CEO of Susan G. Komen for the Cure. Brinker started Komen for the Cure in 1982 after promising her dying sister, Susan G. Komen, that she would do everything possible to battle breast cancer. The organization has since invested more than \$1.9 billion in research, education, screening and treatment, and its activism has led to new legislation and greater government research funding. Brinker's creativity has led to revolutionary efforts such as Susan G. Komen Race for the Cure and cause-related marketing. In 2009, President Obama honored her with the Presidential Medal of Freedom, the nation's highest civilian honor. She was also named Goodwill Ambassador for Cancer Control for the United Nations' World Health Organization, where she continues working to put cancer control at the top of the world health agenda. The author of the best-seller "Promise Me," she was named one of Time's "100 Most Influential People" in 2008. A member of the Council on Foreign Relations, she has received numerous accolades for her work.



DEBORAH BROOKS is co-founder and executive vice chairman of The Michael J. Fox Foundation for Parkinson's Research (MJFF). Brooks launched MJFF with Michael J. Fox and served as the foundation's president and CEO from October 2000 to February 2007. She oversees the foundation's fundraising, communications and digital strategy teams. Brooks serves on the boards of *FasterCures'* Philanthropy Advisory Service and the School of Social Policy and Practice at the University of Pennsylvania. She is also a past director of the Parkinson's Action Network. Brooks started her career at Goldman, Sachs & Co., where she spent nine years as vice president in the fixed-income and asset-management divisions. She holds a bachelor's degree in economics from the College of William and Mary, an M.B.A. from the Tuck School at Dartmouth College and a master's in marital and family therapy from Northwestern University.



TIMOTHY RAY BROWN is the founder of the Timothy Ray Brown Foundation of the World AIDS Institute. The foundation has a single goal: to find a cure for HIV. In 1995 Brown was diagnosed with HIV while attending school in Berlin. For the next 11 years, doctors treated him with anti-retroviral therapy. In 2006, however, he was diagnosed with acute myeloid leukemia and underwent chemotherapy. While the first round of treatment appeared to work, it also made him more susceptible to infections such as pneumonia and sepsis. His doctors realized they would have to try a different approach. His oncologist, Dr. Gero Hutter of the Charite Hospital in Berlin, opted to give Brown a stem cell transplant to treat his leukemia. But rather than choosing a matched donor, he used the stem cells of a donor who had what is known as a CCR5 mutation - a mutation that makes cells immune to HIV. In results later published in the *New England Journal of Medicine*, Hutter and his colleagues reported that the transplant not only treated Brown's leukemia but had also eliminated the HIV from his system.



RENZO CANETTA is vice president of oncology global clinical research at Bristol-Myers Squibb. A graduate of the University of Milan, he is board-certified in clinical and laboratory hematology. Since joining Bristol-Myers Squibb in 1980, Canetta has held numerous leadership roles, including head of clinical cancer research and head of development, life cycle management. His experience can be best summarized by the clinical development leading to the acceptance by health authorities and the introduction to the medical practice of 14 new anticancer agents and two new anti-viral drugs. His area of expertise relates to cancer patient care, diagnosis and experimental treatment of hematologic malignancies and solid tumors, methodology of clinical trials, and new drug development. Canetta worked at the Istituto Nazionale Tumori in Milan, Italy, from 1974 to 1980. His research focus was on clinical trials in lymphomas and gastrointestinal tumors.



ERIC CANTOR is the majority leader in the U.S. House of Representatives and has been Virginia's 7th District congressman since 2001. Elected majority leader in the wake of the 2010 midterm elections, Cantor was previously the Republican whip. Named one of The Weekly Standard's "Young Guns of the House GOP," he is a co-author of the New York Times best-seller "Young Guns: A New Generation of Conservative Leaders." His commentary on the economy, health care and foreign policy has been featured in many major publications. A proponent of strong national defense, Cantor formerly chaired the Congressional Task Force on Terrorism and Unconventional Warfare. He has worked to lower taxes, eliminate excessive regulation and encourage entrepreneurship, and authored the Tax Relief and Health Care Act of 2006, which made it easier for families to save for health-care needs through health savings accounts. Cantor holds a bachelor's degree from George Washington University, a J.D. from William & Mary and a master's degree from Columbia University.



BEN CARDIN is a U.S. senator from Maryland. A leader on health care, retirement security, the environment and fiscal issues, the Democrat serves on the Foreign Relations, Finance, Environment and Public Works, Budget and Small Business committees. In the Senate, he introduced legislation to repeal Medicare's annual caps on physical therapy and other rehabilitation services. He also sought to allow individuals between the ages of 55 and 64 to buy into the program. In the House, his bill to expand Medicare to include preventive benefits such as colorectal, prostate, mammogram and osteoporosis screening was enacted into law. He also authored legislation to improve the drug benefit for seniors, guarantee coverage for emergency services and fund graduate medical education. In 2009, Cardin succeeded in getting a guaranteed dental benefit included in the Children's Health Insurance Program (CHIP) reauthorization. The Affordable Care Act included his amendment to elevate the National Center on Minority Health and Health Disparities to an institute in the National Institutes of Health.



JARED CARNEY is CEO of Lightdale, LLC, which he founded after nine years with the Milken Institute. As the Institute's chief strategy officer, he was responsible for more than 1,000 percent revenue growth. Carney created innovative programs and partnerships that accelerated progress toward the goals of job creation, advancing medical research and expanding access to capital. Among other initiatives, he spearheaded the annual Global Conference and the establishment of the Global Capital Markets Advisory Council (GCMAC) and the Milken Institute Asia Center in Singapore. Carney remains affiliated with the Institute and *FasterCures* as a senior fellow, and retains responsibility for GCMAC and the Asia Center. Previously, he worked in the high-tech and media industries, having been introduced to the world of cutting-edge innovation while working for Richard Saul Wurman, founder of the TED Conferences. Dubbed an Internet pioneer by Wired magazine, Carney co-started Intranets.com, an Idealab company acquired by WebEx, and ran business development at Captura, sold to Concur Technologies.

A CELEBRATION OF SCIENCE



S. WARD CASSCELLS is the Tyson Distinguished Professor of Medicine and Public Health, vice president for public policy at the University of Texas, Houston and senior scholar at the Texas Heart Institute. A decorated Army officer who served in Iraq, he was the assistant secretary of defense (health affairs). Casscells was awarded the Defense Department's highest civilian award, the Distinguished Public Service Medal, as well as the Surgeon General's Medallion from the Department of Health and Human Services and the Army's Decoration for Distinguished Civilian Service. A graduate of Yale and Harvard Medical School, he writes about heart attack prevention, IT, medical ethics, influenza, disaster preparedness, nanotechnology and health policy. He also speaks publicly about living with cancer. An inventor and founder of several companies, he has served on numerous civic, corporate and professional boards. He received the 2010 Pike Humanitarian Prize, the 2011 Cancer Forward award and the 2012 Lifetime Achievement Award from the Houston Technology Center.



DAN CERUTTI is vice president of IBM's Watson for Healthcare cross-industry initiative, having led the startup effort within the company to commercialize the Watson DeepQA/Jeopardy! technologies. Cerutti was previously general manager of IBM Smart Business, a brand of solutions for small and medium-size organizations, and IP Licensing, responsible for intellectual property transactions related to IBM patents and software. He has been involved in leading-edge technologies for 25 years and participated in the formation and growth of a dozen businesses. Cerutti was CEO of Cylant, a security technology company sold to Reflex Security; founder and CEO of Veridiem, a marketing analytics company sold to SAS; and founder and CEO of Amulet, an Internet pioneer that created an automated research service called InfoWizard. He holds computer science degrees from Harvard University and Syracuse University and is the author of the textbook "Distributed Computing Environments."



JEAN-LOU CHAMEAU is president of the California Institute of Technology, one of the world's preeminent centers of education and research in engineering and science. Caltech also operates such renowned facilities as the Keck Observatory and, in partnership with NASA, the Jet Propulsion Laboratory. At the Georgia Institute of Technology, Chameau was provost, dean of the College of Engineering and director of the School of Civil and Environmental Engineering. He also served as president of Golder Associates, a geotechnical consulting company, and was a faculty member at Purdue University. He serves on the boards of MTS Systems Corp., Safran SA and John Wiley & Sons, Inc. Chameau is a member of the U.S. National Academy of Engineering and the French Académie des Technologies. A native of France, Chameau received his graduate degree in civil engineering at Stanford University.



PETER CHIARELLI is CEO of One Mind for Research and a retired U.S. Army general. An advocate for service members and veterans suffering with post-traumatic stress and traumatic brain injuries, Chiarelli and his nonprofit organization are focused on rapidly developing new treatments for brain disorders. Prior to joining One Mind for Research, he was the Army's vice chief of staff (2008-2012), overseeing the implementation of recommendations related to the Army's behavioral health activities, specifically the Health Promotion, Risk Reduction and Suicide Prevention program. Chiarelli also served as the senior military assistant to the secretary of defense (2007-2008). During the Iraq war, Chiarelli was responsible for the day-to-day combat operations of 147,000 U.S. and coalition troops and pioneered efforts to restore government services and economic stability. He holds a B.S. from Seattle University, an M.P.A. from the University of Washington and an M.A. in national security strategy from Salve Regina University.



STEVEN CHU is the U.S. secretary of energy, charged with helping implement President Obama's plans to invest in clean energy, reduce U.S. dependence on foreign oil and address the global climate crisis. Chu is the co-recipient of the 1997 Nobel Prize for Physics and many other awards. He has devoted his recent scientific career to the search for solutions to our energy and climate challenges - a mission he continues with even greater urgency as the secretary of energy. Prior to being appointed secretary, Chu was the director of the Department of Energy's Lawrence Berkeley National Lab, where he led the lab in pursuit of alternative and renewable energy technologies. He also taught at the University of California as a professor of physics, molecular biology and cell biology. Previously, he held positions at Stanford University and AT&T Bell Laboratories. Chu is a member of the National Academy of Sciences. He holds bachelor's degrees in mathematics and physics from the University of Rochester and a Ph.D. in physics from the University of California, Berkeley, as well as 23 honorary degrees.



TIMOTHY COETZEE is the chief research officer of the National Multiple Sclerosis Society. He is responsible for the society's research program, which funds more than 375 projects around the world. Most recently, he served as president of Fast Forward, the society's venture philanthropy. Coetzee was instrumental in the founding and establishment of Fast Forward. In this capacity, Coetzee was responsible for the society's strategic funding of biotechnology and pharmaceutical companies as well as partnerships with the financial and business communities. Prior to Fast Forward, Coetzee led the society's translational research initiatives on nervous system repair and protection in MS as well as the society's programs to recruit and train physicians and scientists in MS research. Coetzee received his Ph.D. in molecular biology from Albany Medical College in 1993. He joined the National MS Society's home office staff in the fall of 2000.

A CELEBRATION OF SCIENCE



FRANCIS COLLINS is director of the National Institutes of Health, overseeing the work of the world's largest supporter of biomedical research. A physician-geneticist noted for his landmark discoveries of disease genes, he led the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at the NIH from 1993 to 2008. Before coming to the NIH, Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the Institute of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in 2007, and received the National Medal of Science in 2009.



MICHAEL CROW became president of Arizona State University in 2002. Since then, he has designed the transformation of ASU into a highly innovative, high-speed adaptive knowledge enterprise that combines academic excellence, inclusiveness and societal impact - a model he terms the "New American University." During his tenure, ASU has established major new transdisciplinary schools and research initiatives, and witnessed an unprecedented academic infrastructure expansion, the tripling of research expenditures and the attainment of record levels of diversity. He was previously executive vice provost and professor of science policy at Columbia University. A fellow of the National Academy of Public Administration, he is the author of books and articles analyzing knowledge enterprises and science and technology policy. He also is founding director and chairman of In-Q-Tel.



JEFFREY CUMMINGS is director of the Cleveland Clinic Lou Ruvo Center for Brain Health, a clinical care, translational research and clinical trials enterprise specializing in the care of patients with neurocognitive deficits and development of therapies for neurodegenerative disorders. Cummings' expertise covers clinical trial design and analysis, global trial implementation and trial outcome measures. He developed the Neuropsychiatric Inventory, the most commonly used tool for clinical trials characterizing behavioral disturbances in dementia syndromes. Cummings completed his neurology residency and a fellowship in behavioral neurology at Boston University, followed by a research fellowship in neuropathology and neuropsychiatry at the National Hospital for Nervous Diseases in London. Cummings was formerly a professor of neurology and psychiatry at UCLA, where he directed the Mary S. Easton Center for Alzheimer's Disease Research, and the Deane F. Johnson Center for Neurotherapeutics. He has authored or edited more than 30 books and published 600 peer-reviewed papers.

RENEWING OUR COMMITMENT TO THE FUTURE



DIANE DAMIANO is a tenure-track scientist and chief of the functional and applied biomechanics section in the Rehabilitation Medicine Department at the National Institutes of Health. Her research is devoted to rehabilitation programs to promote optimal motor functioning and enhance muscle and neural plasticity in children with cerebral palsy. Damiano is the former president of the American Academy of Cerebral Palsy and Developmental Medicine and also of the Gait and Clinical Movement Analysis Society. She is on the Editorial Board of Developmental Medicine and Child Neurology, Neurorehabilitation and Neural Repair and the Journal of Pediatric Rehabilitation Medicine. She has published more than 75 peer-reviewed articles and book chapters. Damiano holds a Ph.D. in research methods and biomechanics from the University of Virginia, an M.S. in physical therapy from Duke University and an undergraduate degree in biological sciences from Catholic University.



TOM DASCHLE is a senior policy advisor at DLA Piper. He served his home state of South Dakota in the U.S. Senate from 1987 to 2005. Daschle is the only senator to have served twice as both majority and minority leader. In addition, Daschle serves as vice chair of the National Democratic Institute, and he is a co-founder of the Bipartisan Policy Center and a distinguished fellow at the Center for American Progress. He is the author of "Like No Other Time: The 107th Congress and the Two Years That Changed America Forever," "Critical: What We Can Do About the Health-Care Crisis" and "Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform."



SUSAN DENTZER is the editor-in-chief of Health Affairs, the nation's leading journal of health policy, and is an on-air analyst on health issues with the "PBS NewsHour." She previously led the "NewsHour's" health unit, reporting extensively on-air about health-care reform. She is an elected member of the Institute of Medicine and the Council on Foreign Relations. Dentzer graduated from Dartmouth, is a trustee emerita of the college, and chaired the Dartmouth Board of Trustees from 2001 to 2004. She currently serves as a member of the Board of Overseers of Dartmouth Medical School and is an overseer of the International Rescue Committee, a leading humanitarian organization. She is also on the board of directors of Research!America, an alliance working to make research to improve health a higher priority.



RONALD DEPINHO is president of the University of Texas MD Anderson Cancer Center. His research has focused on the molecular underpinnings of cancer, aging and degenerative disorders and the translation of such knowledge into clinical advances. DePinho's scientific career began at the Albert Einstein College of Medicine, where he was the Feinberg senior scholar in cancer research. He then joined the Department of Medical Oncology at the Dana-Farber Cancer Institute and the Harvard Medical School. At Harvard, he was the founding director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and a professor of medicine and genetics. His honors and awards include the March of Dimes Basil O'Connor Award, the James S. McDonnell Scholar Award and the Cancer Research Institute Scholar Award. A member of the National Academy of Sciences, DePinho is a founder of Aveo Pharmaceuticals and a number of companies focused on cancer therapy and diagnostics. DePinho studied biology at Fordham University and received his M.D. from the Albert Einstein College of Medicine.



ROSS DEVOL is chief research officer at the Milken Institute. He oversees research on international, national and comparative regional growth performance, technology and its impact on regional and national economies, access to capital and its role in economic growth and job creation, and health-related topics. He was the principal author of "An Unhealthy America: The Economic Burden of Chronic Disease," which brought to light the economic losses associated with preventable illnesses and estimated the avoidable costs if a serious effort were made to improve Americans' health. He also authored "America's High-Tech Economy: Growth, Development and Risks for Metropolitan Areas" and created the "Best-Performing Cities Index," an annual ranking of U.S. metropolitan areas that shows where jobs are being created. Other recent work involves the study of biotechnology and life-science clusters and their impact on regional economies. DeVol was previously senior vice president of Global Insight Inc.



PETER DIAMANDIS is chairman and CEO of the X PRIZE Foundation, a nonprofit focused on designing and launching large incentive prizes to drive radical breakthroughs for the benefit of humanity. Diamandis is an international leader in the commercial space arena, having founded and run many of the field's leading companies. He is the author of the New York Times bestseller "Abundance: The Future Is Better Than You Think." Diamandis' mission is to open the space frontier for humanity. His personal motto is: "The best way to predict the future is to create it yourself!" Diamandis holds a bachelor's degree in molecular genetics and a graduate degree in aerospace engineering from the Massachusetts Institute of Technology, and an M.D. from Harvard Medical School. In 2005 he was awarded an honorary doctorate from the International Space University.



RICHARD DITIZIO recently joined the Milken Institute as executive director of program development after a 25-year career in banking. He most recently served as CEO of Citi Private Bank, an 1,100-employee unit of Citigroup. Prior to that, Ditizio ran the North American UHNW practice for the bank, leading 24 offices across the U.S. and Canada. In these roles, he counseled clients across a continuum of issues, including business succession, philanthropy and raising children amid affluence. His work with UHNW families has been widely profiled in such media outlets as the Wall Street Journal, Financial Times, Lifestyles, CNBC and Reuters; he has been the featured speaker at engagements for the Jewish Funders Network, Tiger 21 and others. A recipient of the NSFRE Corporate Executive award, Ditizio has been involved with numerous nonprofit boards and charitable organizations throughout his career.



FRANK DOUGLAS is president, CEO and chief strategist of the Austen BioInnovation Institute in Akron (Ohio), a biomaterials institute built on a unique collaboration of five medical and educational institutions. He is a member of the Ewing Marion Kauffman Foundation's Board of Trustees, a senior partner emeritus of PureTech Ventures and the national chairman of the Value-driven Engineering initiative. Douglas is also a professor at the University of Akron and Northeast Ohio Medical University. Formerly, he was executive vice president, chief scientific officer and a member of the board of management of Aventis, where he headed drug innovation and approval, with responsibility for research, development and regulatory and marketing support. At the Massachusetts Institute of Technology, he founded and served as first executive director of the Center for Biomedical Innovation. With nearly three decades of experience in health care, pharmaceuticals and entrepreneurship, Douglas has received numerous awards. He earned his Ph.D. and M.D. from Cornell University.



KAFUI DZIRASA is an assistant professor in the Department of Psychiatry and Behavioral Science at the Duke University School of Medicine. His research interests focus on understanding how changes in the brain produce neurological and mental illness, and his graduate work has led to several distinctions including the Somjen Award for Most Outstanding Dissertation Thesis, the Ruth K. Broad Biomedical Research Fellowship, the UNCF/Merck Graduate Science Research Fellowship and the Wakeman Fellowship. Dzirasa's ultimate goal is to combine his research background, medical training and community experience to improve outcomes for communities suffering from neurological and psychiatric illness. A product of the nationally renowned Meyerhoff Scholarship program at the University of Maryland Baltimore County, he completed his Ph.D. in neurobiology at Duke University in 2007. In 2009, Dzirasa obtained an M.D. from Duke.

A CELEBRATION OF SCIENCE



KENNY "BABYFACE" EDMONDS is a music producer, songwriter and recording artist. A 10-time Grammy winner with 11 solo albums, Edmonds has been behind more than 125 Top 10 R&B and pop hits, with single and album sales exceeding 500 million units worldwide. Many celebrated vocalists have recorded his work, among them Whitney Houston, Madonna, Michael Jackson and Beyonce. He has been honored by the Soul Train Music Awards, the NAACP Image Awards and the American Music Awards, and was named Entertainer of the Year by Black Entertainment Television. Edmonds' charitable work has likewise earned wide recognition. He has received the Essence Award for Excellence, the City of Hope Award and Variety magazine's Top of the Town Honoree Award for his efforts. He was national spokesman for Boarder Babies and helped fund a transitional home for youths, the Little Blue House, in Washington, D.C. With Antonio "L.A." Reid, Edmonds wrote and produced the song "Just Stand Up," to promote breast cancer awareness. They were honored at the Noble Awards for their contributions to Stand Up to Cancer.



EZEKIEL EMANUEL is the vice provost for global initiatives, the Diane v.S. Levy and Robert M. Levy University Professor and chairman of the Department of Medical Ethics and Health Policy at the University of Pennsylvania. A breast oncologist, Emanuel was chairman of the Department of Bioethics at the National Institutes of Health and served as special advisor on health policy to the director of the Office of Management and Budget and the National Economic Council. He was a member of President Clinton's Health Care Task Force and the National Bioethics Advisory Commission. He co-edited the Oxford Textbook of Clinical Research Ethics and has published widely on the ethics of clinical research, health-care reform, euthanasia and the physician-patient relationship. Emanuel was elected to the National Academy of Sciences' Institute of Medicine and the Association of American Physicians. Among other honors, he received the Public Service Award from the American Society of Clinical Oncology. Emanuel received his M.Sc. from Oxford University and earned his M.D. and Ph.D. at Harvard.



CHAKA FATTAH represents Pennsylvania in the U.S. House of Representatives and serves as a senior member of the House Appropriations Committee, which is responsible for setting spending priorities for over \$1 trillion in annual discretionary funds. Fattah is the ranking member on the Subcommittee on Commerce, Justice, Science and related agencies, which oversees close to \$51 billion in discretionary spending including that of the Commerce and Justice Departments, NASA, NOAA and the National Science Foundation. In 2011, through his role on the Appropriations Committee, Fattah directed the Office of Science and Technology Policy to establish an Interagency Working Group on Neuroscience. Housed in the White House, the working group convenes representatives across the federal government to make recommendations about the future of neuroscience research.



ANTHONY FAUCI is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Since his appointment in 1984, Fauci has overseen an extensive research portfolio devoted to preventing, diagnosing and treating infectious and immune-mediated diseases. Fauci also is chief of the NIAID Laboratory of Immunoregulation, where he has made numerous important discoveries related to HIV/AIDS. He is one of the most cited scientists in that field. A member of the National Academy of Sciences, Fauci has received numerous awards for his scientific accomplishments, including the National Medal of Science, the Mary Woodard Lasker Award for Public Service and the Presidential Medal of Freedom. He has been awarded 38 honorary doctoral degrees and is the author, co-author or editor of more than 1,200 scientific publications, including several major textbooks.



LUIGI FONTANA is a research associate professor of medicine at Washington University in St. Louis and a professor of nutrition at Salerno University Medical School in Italy. An internationally recognized scientist, author and expert in the fields of nutrition and healthy aging, he co-directs the Longevity Research Program at Washington University in St. Louis. He is also director of the Division of Nutrition and Aging of the Italian National Institute of Health. Fontana's research focuses on the role of diet and exercise in preventing age-associated chronic disease such as cancer, diabetes and cardiovascular disease, and on the promotion of healthy successful aging. Fontana graduated from the Verona University Medical School, where he completed his internship and residency in internal medicine. He also received a Ph.D. in metabolism from the University of Padua Medical School.



JOSEPH FORTUNATO is chairman, president and CEO of General Nutrition Centers Inc. Since joining GNC in 1990, he has held various positions within the company, including executive vice president, chief operating officer, senior executive vice president, executive vice president of retail operations and store development, and director of financial operations. Under Fortunato's leadership, GNC was named the IPO of the year in 2011. Fortunato serves on the board of KUE Management Inc., a provider of education programs and services, and Children's Hospital of Pittsburgh Foundation. Prior to joining GNC, he was president of Fortunato and Associates Financial Consulting Group. Fortunato earned his undergraduate degree in finance at Duquesne University in 1975.



MARGARET FOTI is CEO of the American Association for Cancer Research (AACR). During her tenure, AACR has grown to 33,000 members in more than 90 countries. She previously was managing editor of the journal *Cancer Research* and publisher for AACR. Foti is past president of the Society for Scholarly Publishing and the Council of Science Editors. She is a member of the Executive Committee of Friends of Cancer Research, council member of the European Association for Cancer Research and past president of the National Coalition for Cancer Research. Foti has received numerous honors for her contributions to cancer research, including the European CanCer Organisation Lifetime Achievement Award, the inaugural Kripke Legend Award for contributions to the advancement of women in the field and the American Society of Clinical Oncology's Special Recognition Award. Most recently, Foti received the 2012 Biotech Humanitarian Award and the Pinnacle Award from the Millay Club in Pennsylvania. She holds a B.A., M.A. and Ph.D. from Temple University and has been awarded several honorary doctorate degrees.



LEVI GARRAWAY is an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute of Harvard Medical School. In addition, he is a senior associate member of the Broad Institute, where he leads several large cancer genome analyses and functional genomics efforts. Garraway has also researched drug resistance and genomics-driven (or “personalized”) cancer medicine. He published the first genome sequencing studies of aggressive primary prostate cancer and has led other major sequencing initiatives in melanoma and head-and-neck cancers. Garraway's honors include the Career Award in the Biomedical Sciences from the Burroughs-Wellcome Fund. Garraway received his A.B. in biochemical sciences from Harvard College in 1990 and his M.D. and Ph.D. from Harvard Medical School in 1999. He completed his internship and residency in internal medicine at the Massachusetts General Hospital, where he also served as medical chief resident in 2003. He received fellowship training in medical oncology at Dana-Farber.



JAMES GERAGHTY is senior vice president and an officer of Genzyme Corp. He was president of Genzyme Europe from 1998 to 2002, and general manager of Genzyme's cardiovascular business from 2003 to 2008. From 2008 to 2010, he oversaw strategic initiatives in emerging markets and led most of Genzyme's major strategic transactions. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases program. He served as co-chair of the executive committee for BIO 2007 and was a founder of the Partnering for Global Health Forum. He is currently on the boards of MMV North America and Bio Ventures for Global Health. Earlier in his career, Geraghty was chairman and CEO of GTC Biotherapeutics, which he took public in 1993. Prior to that, he led health-care strategy teams at Bain & Company and early-stage investments for Bain Capital. A graduate of Yale Law School, he holds a master's degree from the University of Pennsylvania and a bachelor's degree from Georgetown University.



RICHARD GIBBS is the director of the Human Genome Sequencing Center (HGSC) and the Wofford Cain professor of human and molecular genetics at the Baylor College of Medicine. The HGSC is one of three National Institutes of Health-funded genome centers involved in the completion of the first human genome sequence in 2004. Gibbs established the HGSC in 1996, when Baylor was chosen as one of six sites to complete the final phase of the project. The HGSC is now working to sequence and annotate the genome of the cow, using a whole genome shotgun approach, and other important organisms. He joined the faculty at Baylor College of Medicine (BCM) in 1991, and played a key role in the early planning and development phases of the International Human Genome Project. As a postdoctoral fellow at the BCM, he studied the molecular basis of human X-linked diseases to develop technologies for rapid genetic analysis. He also developed several fundamental technologies for nucleic acid analysis. Gibbs holds a B.Sc. and a Ph.D. in genetics and radiation biology from the University of Melbourne.



WHOOPI GOLDBERG, one of America's most popular actors, has won a Grammy, an Academy Award, two Golden Globes, an Emmy, a Daytime Emmy and a Tony. A UNICEF Goodwill Ambassador to the United Nations, she is also an outspoken humanitarian activist, working on behalf of children, the homeless, the battle against AIDS and many other causes. Her long career in film has been highlighted by "The Color Purple," "Sister Act," "Ghost," "Corrina, Corrina," "The Lion King" and "For Colored Girls." On television, among other credits, she has appeared in "Star Trek: The Next Generation," hosted a syndicated late-night talk show and starred in the NBC sitcom "Whoopi," which she executive produced. Currently, she is a host of ABC's "The View." Goldberg has penned numerous books for children and adults, and her second work, "Book," achieved bestseller status. Goldberg's hands, feet and braids are imprinted in the forecourt of Grauman's Chinese Theatre, and she was honored with a star on the Hollywood Walk of Fame.



LYNN GOLDMAN is dean of the School of Public Health and Health Services at The George Washington University. Before joining GWU in 2010, she was a professor of environmental health sciences at Johns Hopkins University's Bloomberg School of Public Health. Prior to that, Goldman served as assistant administrator for the EPA's Office of Chemical Safety and Pollution Prevention, where she was responsible for national implementation of chemical and pesticide safety and pollution prevention laws. She also worked at the California Department of Public Health, where she headed the Division of Environmental and Occupational Disease Control. Goldman serves on the board of the Environmental Defense Fund and is a member of both the Institute of Medicine and the National Academy of Sciences Board on Environmental Sciences and Toxicology. She holds a B.S. in conservation of natural resources and an M.S. in health and medical science from the University of California, Berkeley; an M.P.H. from the Johns Hopkins University; and an M.D. from the University of California, San Francisco.

A CELEBRATION OF SCIENCE



TED GOLDSTEIN is a Ph.D. candidate in biomolecular engineering at the University of California, Santa Cruz, working on a theory of cancer's molecular processes. He is a member of UCSC's Haussler and Stuart laboratories, several National Institutes of Health TCGA data analysis teams and Stand Up to Cancer Dream Teams. Goldstein is a former vice president of developer tools at Apple Inc., where his team created the Xcode development system and the Mac OS X and iOS runtime systems. Prior to Apple, he led the electronic commerce and smart card efforts in the former Sun Microsystems Inc.'s JavaSoft business. There he created Java Card, the world's most popular smart card platform, used for e-commerce, GSM phones and U.S. government identification. He has proposed MedBook, a Facebook-like system that would unite cancer patients, their doctors and researchers in the war against cancer.



GARY GOTTLIEB is president and CEO of Partners HealthCare. Gottlieb is a professor of psychiatry at Harvard Medical School and a member of the Institute of Medicine of the National Academies. He served as president of Brigham and Women's/Faulkner Hospitals, president of North Shore Medical Center and chairman of Partners Psychiatry. Gottlieb has also served as executive vice chair of psychiatry and associate dean for managed care at the University of Pennsylvania medical center and director and CEO of Friends Hospital in Philadelphia. A leader in the Boston-area community, Gottlieb chairs the Private Industry Council, the city's workforce development board. He is also a member of the boards of the Federal Reserve Bank of Boston and Partners in Health.



JAMES GREENWOOD is president and CEO of the Biotechnology Industry Organization (BIO) and a former member of Congress. BIO represents more than 1,200 companies, academic institutions and other organizations in the United States and abroad. Since his appointment in 2005, he has greatly expanded the trade association, helping to transform it into a world-class advocacy group playing a leading role in shaping public policy on issues crucial to the industry. From 1993 to 2005, Greenwood represented Pennsylvania's 8th District in the House of Representatives. As a senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. He chaired the panel's subcommittee on oversight and investigation, leading probes into corporate governance at Enron, terrorist threats to infrastructure and waste and fraud in government agencies. Prior to Congress, Greenwood served in the Pennsylvania General Assembly and Senate and was a caseworker with abused and neglected children. He earned his bachelor's degree at Dickinson College.



EDWARD GREISSING is the vice president of North American corporate affairs for Sanofi US. He is responsible for the Chronic Disease Prevention and Wellness Program, health innovation, academic and scientific affairs, government relations, public policy, reimbursement, global institutional relations, regional and local alliance development, patient advocacy, civic action, and corporate social responsibility. Prior to joining Sanofi US, he was president and CEO of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food-service and financial industries. Before Red Line, he spent 25 years building a business-focused global government affairs organization for Upjohn that eventually became Pharmacia. Previously Greissing was a staff member of the U.S. Senate Intelligence Committee and a member of the honor detail for the 561st Military Police Company in the U.S. Army. Greissing is a graduate of Holy Cross and received his master's degree in congressional studies and politics from Catholic University of America.



STEPHEN GRUBER, a board-certified medical oncologist and cancer geneticist, serves as director of the USC Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles. An internationally recognized expert in hereditary cancer syndromes, Gruber's research concentrates on genetic susceptibility to cancer and strategies to reduce the burden of cancer in families with cancer and in populations at risk. Gruber's work has been continuously funded by the National Institutes of Health since 1998. A graduate of the University of Pennsylvania, he holds a Ph.D. in epidemiology and an M.P.H. from Yale University as well as an M.D. from the University of Pennsylvania Medical School.



GORDON GUND is chairman and co-founder of the Foundation Fighting Blindness, the largest nonprofit, non-governmental supporter of research on retinal degenerative disease in the world. Its mission is to find preventions, treatments and cures for blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Stargardt's disease, Usher syndrome and allied retinal degenerative diseases. Collectively, they affect more than 10 million people in the United States and millions more worldwide. Since its inception in 1971, the foundation has raised more than \$450 million to support its goal. It funds innovative research in a number of scientific areas, including stem cell therapies, genetics and gene therapy, neuroprotection and nutrition, conducted at 71 institutions, eye hospitals and universities around the world. Its subsidiary, the FFB Clinical Research Institute, funds and facilitates the translation of promising therapies from the laboratory to the clinic. Gund is also the lead board director of Corning, Inc. and Kellogg Co.



MARGARET HAMBURG is commissioner of the U.S. Food and Drug Administration (FDA), where she has served since May 2009. As FDA commissioner, she is advancing regulatory science, medical product innovation and globalization of the agency, while overseeing the implementation of groundbreaking laws to curb the use of tobacco and enhance food safety. She has undertaken major efforts to streamline and modernize the FDA's regulatory pathways. Before joining the FDA, Hamburg was vice president and senior scientist at the Nuclear Threat Initiative. In the 1990s, as New York City's health commissioner, she launched several major initiatives, including the nation's first public health bioterrorism preparedness program and an internationally recognized program to curtail the resurgence and spread of tuberculosis. President Clinton later named her assistant secretary for planning and evaluation in the U.S. Department of Health and Human Services. Hamburg earned her M.D. from Harvard Medical School.



FRED HASSAN is a partner and managing director of the private equity firm Warburg Pincus. Hassan serves as chairman of Bausch & Lomb and as a board member of Time Warner and Avon, where he is lead director. He is the former chairman and CEO of Schering-Plough Corp. Before Schering-Plough, Hassan was chairman and CEO of Pharmacia Corp., which was formed in 2000 after the merger of Monsanto and Pharmacia & Upjohn, where Hassan was CEO. Previously, he was an executive vice president of Wyeth (formerly American Home Products) with responsibility for its pharmaceutical and medical products business. Hassan also spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business. A member of The Business Council, Hassan has chaired the Pharmaceutical Research and Manufacturers of America (PhRMA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), among other organizations. He holds a B.S. from the University of London and an M.B.A. from Harvard Business School.



JIM HEALY is managing general partner of Sofinnova. He has over 20 years of experience in biomedical research, development and finance. He specializes in financing late-stage drug development and pharmaceutical spinoffs. Healy invests in private equity and small-cap public financings, and serves or has served on the boards of companies in Belgium, Ireland, Switzerland and the United States. He currently serves on the boards of Amarin (AMRN), Anthera (ANTH), Durata (DRTX), Intermune (ITMN) and Sorbent. He has financed and been a board member of six companies that received either FDA or EMA approval to market their drugs. Healy graduated with a B.A. in molecular biology from the University of California, Berkeley. He received his M.D. and Ph.D. in immunology from the Stanford University School of Medicine through the NIH Medical Scientist Training Program. He also performed neuroscience research at the University of Virginia School of Medicine. Healy has authored or co-authored 13 peer-reviewed articles and invited reviews, including three papers published in Nature.



DAVID HEBER is a professor of medicine and public health and the director of the UCLA Center for Human Nutrition at the David Geffen School of Medicine at the University of California, Los Angeles. He is also chief of the Division of Clinical Nutrition in the Department of Medicine. Heber is an internist and endocrinologist and is certified as a physician specialist in nutrition. He has been repeatedly voted one of the "Best Doctors in America." He has written more than 200 peer-reviewed scientific articles and directed two NIH Center grants on nutrition and cancer and botanical dietary supplements as well as a training grant on nutrition and obesity. He has edited numerous textbooks including "Nutritional Oncology" (Academic Press) in 2006, and four books for the public including "What Color is Your Diet?" (Harper Collins) and "The L.A. Shape Diet" (Harper Collins). His research area is prevention and treatment of common forms of cancer.



SHARON HILLIER is a professor and vice chair in of the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine. Her work is focused on prevention of HIV. Since 2006, she has directed a clinical trials network, the Microbicide Trials Network, which includes an international team of investigators and community and industry partners from seven countries and three continents and is funded by the National Institutes of Health. Hillier serves as chair of the NIH Office of AIDS Research (OAR) Advisory Council, which advises the U.S. secretary of health and human services, the assistant secretary for health, the director of NIH and the director of OAR on AIDS research programs, and the development and annual review of the comprehensive plan for the conduct and support of all AIDS activities of the agencies of NIH. She has twice delivered presentations on HIV prevention to the President's Advisory Council on HIV/AIDS.



JOHN HOLDREN is assistant to President Obama for science and technology, director of the White House Office of Science and Technology Policy and co-chairman of the President's Council of Advisors on Science and Technology. Prior to joining the administration in January 2009, Holdren held dual professorships at Harvard University in the Kennedy School of Government and the Department of Earth and Planetary Sciences for 13 years. For 23 years before that, Holdren co-led the campuswide graduate-degree program in energy and resources at the University of California, Berkeley. He is a member of the National Academy of Sciences, the National Academy of Engineering and the American Academy of Arts and Sciences, as well as a foreign member of the Royal Society of London.

A CELEBRATION OF SCIENCE



STENY HOYER, a Maryland congressman in the U.S. House of Representatives, is a strong advocate of Democratic policies to strengthen America's middle class, its economy and its national security. As House Democratic whip for the 112th Congress, Hoyer is the second-ranking member of the House Democratic leadership. He is charged with mobilizing the party vote on important legislation, acting as a liaison between members and the Democratic leadership and coordinating strategy within the caucus. He also plays a key role in shaping House Democrats' legislative priorities and delivering the Democratic message. Hoyer served as House majority leader from 2007 to 2011 and House Democratic whip from 2003 to 2007.



MICHAEL IDELCHIK is vice president of advanced technologies for GE Global Research, the centralized research and development organization of General Electric Co. In that capacity, he oversees the company's longest-range technology endeavors. Idelchik started with GE in 1978, progressing through various engineering and management roles within the Aircraft Engines, Healthcare and Lighting divisions. In 2002, he founded GE's first integrated technology center in China and served as managing director prior to assuming his current role. In January 2006, GE Chairman and CEO Jeffrey Immelt presented Idelchik with the Chairman's Award for Technology Leadership, recognizing a lifetime of achievement in driving innovation and growth.



DANIEL INOUE is a U.S. senator from Hawaii, the most senior member of the chamber and its president pro tempore. He serves as chairman of the Appropriations Committee and the Defense Appropriations Subcommittee. He is also the ranking Democrat on the Commerce, Science and Transportation Committee and the Indian Affairs Committee and sits on the Rules Committee. In 2011, the government of Japan made Inouye the seventh American and the first of Japanese descent to receive the Grand Cordon of the Order of the Paulownia Flowers, the highest award in the Order of the Rising Sun. He helped establish the Interparliamentary Exchange Program between the U.S. Senate and Japan's legislature. Inouye has championed the interests of Hawaii's people by strengthening the state's infrastructure, diversifying its economy and protecting its natural resources. He was first elected to the Senate in 1962 and is in his ninth consecutive term. Inouye is a World War II veteran, having served with the 442nd Regimental Combat Team. He earned the nation's highest award for military valor, the Medal of Honor.



TYLER JACKS is director of the David H. Koch Institute for Integrative Cancer Research and professor of biology at MIT and a Howard Hughes Medical Institute investigator. The biomedical scientist developed mouse models of human cancer that carry mutations in oncogenes and tumor suppressors implicated in many human cancers, demonstrating the decisive roles of such cancer genes through the development of genetically engineered mouse models of lung, pancreas and brain cancers. Jacks served as an advisor to the National Cancer Institute and was president of the American Association for Cancer Research. He oversaw the transformation of the Center for Cancer Research at MIT into the Koch Institute for Integrative Cancer Research, bringing together cancer biologists and bioengineers. He is a member of the National Academy of Sciences and the Institute of Medicine of the National Academies.



EARVIN (MAGIC) JOHNSON is chairman and CEO of Magic Johnson Enterprises. An NBA legend and two-time Hall of Famer, Johnson has successfully parlayed his skills and tenacity on the court into the business world, propelling his company to the No. 1 urban brand in America. Magic Johnson Enterprises provides quality products and services that focus primarily on ethnically diverse and underserved urban communities through strategic alliances, investments, consulting and endorsements. The conglomerate is composed of multiple business entities and partnerships that include Canyon Johnson, a \$1 billion real estate fund; Yucaipa Johnson, a \$500 million private equity fund, and ASPIRE, his newly announced African-American television network. Johnson also serves as chairman and founder of the Magic Johnson Foundation, where his unwavering commitment to transform urban America continues through HIV/AIDS awareness and prevention programs, community empowerment centers, and the Taylor Michaels Scholarship Program.



DONALD JONES is vice president of global strategy and market development at Qualcomm Life, responsible for wireless technologies and platforms in the health, fitness and life sciences markets. He is the founder and chairman of the Wireless Life Sciences Alliance. A member of the World Economic Forum Global Agenda Council on Digital Health, he sits on the boards of the Alliance Healthcare Foundation and the American Telemedicine Association. Jones was a founding board member of the West Wireless Health Institute, the first institute focused on the clinical efficacy and economic efficiencies of wireless technologies in health care. Jones has been called one of San Diego's "Top Influentials" by The Daily Transcript and one of the "10 Disruptive Forces in Health IT" by Fierce Health IT. In early 2010, he was named to the Consumer Products Innovations Board at Sanofi. Jones holds multiple issued and pending patents. He holds a bachelor's degree from the University of California, San Diego; a J.D. from the University of San Diego; and an M.B.A. from the University of California, Irvine.



CARL JUNE is the Richard W. Vague professor of immunotherapy in the Perelman School of Medicine and director of translational research at the Abramson Cancer Center at the University of Pennsylvania. He also works at the Abramson Family Cancer Research Institute. Board certified in internal medicine and medical oncology, June maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance, cancer gene therapy and adoptive immunotherapy. He is a graduate of the Naval Academy in Annapolis and Baylor College of Medicine in Houston (1979). June's graduate training was in immunology and malaria with Paul-Henri Lambert at the World Health Organization in Geneva from 1978 to 1979, and his post-doctoral training was in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 to 1986.



NEAL KASSELL is the founder and chairman of the Focused Ultrasound Foundation and professor of neurosurgery at the University of Virginia. Earlier, Kassell served on the faculty at the University of Iowa. Kassell is a founder of numerous private ventures, including Interax Inc., the Virginia Neurological Institute, Multimedia Medical Systems, the Neuroclinical Trials Center, Neuroventure Fund and MedSpecialist. He has served on a number of corporate and nonprofit boards, including Eclipsis Corporation, INC Research, the Prostate Cancer Foundation and Virginia National Bank. He is currently a director of InSightec Ltd., the La Gesse Foundation and the Focused Ultrasound Foundation, and is on the editorial boards of Neurosurgery and Stroke. Kassell has been a recipient of the McKenzie Memorial Award of the Canadian Neurosurgical Society and the Grass Award of the Society of Neurological Surgeons. He has published more than 450 scientific papers. Kassell received his undergraduate and medical education at the University of Pennsylvania.



FRANCINE KAUFMAN is chief medical officer and vice president of global clinical, medical and health affairs at Medtronic Diabetes in Northridge, Calif. Until 2009 she was director of the Comprehensive Childhood Diabetes Center and head of the Center for Endocrinology, Diabetes and Metabolism at Childrens Hospital Los Angeles. Kaufman is a distinguished professor emerita of pediatrics and communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California, and an attending physician at Childrens Hospital. She has published more than 220 peer-reviewed and invited publications. In 2005, her book, "Diabesity," was published by Bantam. Kaufman was chair of the National Institutes of Health-funded Studies to Treat (the TODAY Trial) and Prevent (the HEALTHY Trial) Type 2 Diabetes in Youth (STOPP-T2). She was a principal investigator of TrialNet, a multinational consortium evaluating ways to prevent Type 1 diabetes, funded by the NIH. She was instrumental in banning sodas from the Los Angeles Unified School District in 2003.



MICHAEL KLOWDEN is president and CEO of the Milken Institute. He is responsible for dramatically enhancing the Institute's research capabilities and worldwide outreach. During his tenure, the Institute's annual Global Conference has become one of the world's premier business, finance and policy events. Klowden also initiated specialized research centers, including the California Center, the Israel Center and the Center for a Sustainable Energy Future; established a major presence in Washington, D.C., with the founding of *FasterCures* and the new Center for Financial Markets; and expanded the use of Financial Innovations Labs that suggest solutions to specific challenges. Previously Klowden was president of Jefferies Group Inc.; senior partner at Morgan, Lewis & Bockius; and partner at Mitchell, Silberberg & Knupp. He holds a bachelor's degree from the University of Chicago, where he is now a trustee, and a J.D. from Harvard Law School. He has served on numerous for-profit and charitable boards.



STEVEN KNAPP is president of The George Washington University. His priorities include enhancing GWU's partnerships, expanding the scope of its research, strengthening its alumni community, enlarging students' opportunities for public service and leading its transformation into a model of urban sustainability. Previously Knapp taught English literature at the University of California, Berkeley, before serving as dean of arts and sciences and then provost of Johns Hopkins. He serves on many boards, including the Economic Club of Washington, Greater Washington Urban League, World Affairs Council-Washington, D.C., Washington National Cathedral Foundation and Al Akhawayan University in Ifrane, Morocco. He also sits on the senior advisory board of the Northern Virginia Technology Council and the executive committee of the Council on Competitiveness. He is a fellow of the American Academy of Arts and Sciences and a member of the Council on Foreign Relations and the Modern Language Association. He earned his Ph.D. and master's degree from Cornell University and his B.A. from Yale University.



DAVID KOCH is an executive vice president and a board member of Koch Industries Inc., which owns a diverse group of companies involved in refining and chemicals, process and pollution control equipment and technologies, minerals, fertilizers, polymers and fibers, commodity trading and services, forest and consumer products, and ranching. He is the chairman and CEO of Koch Chemical Technology Group, LLC, a leading supplier of process equipment to oil refineries and chemical plants worldwide. A longtime philanthropist, Koch has given to a variety of organizations. Since 2000, he has pledged more than \$750 million to cancer research; medical centers; educational, arts and cultural institutions; and numerous public-policy organizations. He serves on 27 nonprofit boards. Koch earned his bachelor's and master's degrees in chemical engineering from the Massachusetts Institute of Technology.



ALAN KRUEGER is the chairman of President Obama's Council of Economic Advisers, confirmed by the Senate in November 2011. A labor economist, Krueger has published widely on unemployment, the economics of education, income distribution, social insurance, regulation, terrorism, finance and the environment. He has been a research associate of the National Bureau of Economic Research, a member of the editorial board of *Science* and chief economist for the Council for Economic Education. He is the author of "What Makes a Terrorist: Economics and the Roots of Terrorism" and "Education Matters: A Selection of Essays on Education," and co-author of "Myth and Measurement: The New Economics of the Minimum Wage" and of "Inequality in America: What Role for Human Capital Policies?" Before assuming his current position, Krueger was a member of the board of the MacArthur Foundation and a senior scientist for the Gallup Organization. He holds a bachelor's degree from Cornell University, and a master's and a Ph.D. in economics from Harvard University.



JOEL KURTZMAN is a senior fellow at the Milken Institute and executive director of its Center for Accelerating Energy Solutions. Previously he was global lead partner for thought leadership and innovation at PricewaterhouseCoopers. He has also served as executive editor of the *Harvard Business Review*, a member of the editorial board of Harvard Business School Publishing, a business editor and columnist at *The New York Times* and founding editor of *Strategy+Business*. Kurtzman began his career as an international economist at the United Nations, serving as deputy director of its Project on the Future. While at the U.N., he participated in negotiations between India and Union Carbide over the Bhopal disaster and was awarded India's Indira Gandhi Prize. The author of 24 books and hundreds of articles, he received a master's degree from the University of Houston.



PETER KWONG works at the Dale and Betty Bumpers Vaccine Research Center as chief of the Structural Biology Section in the virology laboratory. Kwong has studied the atomic-level structures of the HIV protein, gp120, which resides on the outer surface of the virus, as well as the structure of the primary HIV receptor, CD4. HIV uses gp120 to find and latch on to CD4-containing immune cells in the first step of infection. By using X-ray crystallography, Kwong elucidated the atomic-level structure of gp120 in complex with the CD4 receptor and a neutralizing human antibody. The results of this experiment and discovery were published in the journals *Nature* and *Science* in 1998. Although structural information has not played a large role in vaccine development thus far, Kwong's research may change this. Kwong entered the University of Chicago at age 16 and earned a bachelor's degree in chemistry and physics and a master's degree in biochemistry by age 20. He earned his second master's degree and his doctoral degree in biochemistry and molecular biophysics from Columbia University in New York.



ERIC LANDER is president and founding director of the Broad Institute of Harvard and MIT, a professor of biology at MIT and systems biology at Harvard Medical School, and co-chairman of the President's Council of Advisors on Science and Technology. A geneticist, molecular biologist and mathematician, Lander has been a pioneer in the understanding and medical application of the human genome. He was a principal leader of the international Human Genome Project from 1990 to 2003 and created genomic methods that enabled the discovery of thousands of genes underlying common diseases such as diabetes, cancer and psychiatric disorders. Under his mentorship, an extraordinary cadre of young scientists has become the next generation of leaders in medical genomics. Lander has co-founded several successful biotechnology firms and served on governing and advisory boards for government agencies, academic institutions, scientific societies and corporations. The recipient of numerous awards and honorary degrees, Lander is a member of the National Academy of Sciences and the Institute of Medicine.



STORY LANDIS is the director of the National Institute for Neurological Disorders and Stroke (NINDS). Landis joined the NINDS in 1995 as scientific director and worked to re-engineer the Institute's intramural research programs. As NINDS director, Landis oversees an annual budget of \$1.6 billion that supports research by investigators in public and private institutions across the country, as well as by scientists working in its intramural program. She co-chairs the NIH Blueprint for Neuroscience Research, a roadmap-like effort to support trans-NIH activities in the brain sciences. Before joining NINDS, Landis served on the faculty of Harvard University and Case Western Reserve University. She has garnered many honors, is an elected fellow of the Institute of Medicine, the Academy of Arts and Sciences, the American Association for the Advancement of Science and the American Neurological Association, and in 2002 was elected president of the Society for Neuroscience. In 2007, Landis was named chair of the NIH Stem Cell Task Force. Landis received her undergraduate degree from Wellesley College and her Ph.D. from Harvard University.



ROBERT LANGER is the David H. Koch Institute professor at MIT. Langer has written more than 1,175 articles and has approximately 800 issued and pending patents worldwide. Langer's patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. He served as a member of the Food and Drug Administration's SCIENCE Board from 1995 to 2002 and as its chairman from 1999 to 2002. Langer has received over 220 major awards including the 2006 U.S. National Medal of Science; the Charles Stark Draper Prize, the 2008 Millennium Prize and the 2012 Priestley Medal, the highest award of the American Chemical Society. Parade magazine in 2004 selected Langer as one of six "Heroes whose research may save your life." He received his bachelor's degree from Cornell University in 1970 and his Sc.D. from MIT in 1974, both in chemical engineering.

A CELEBRATION OF SCIENCE



RISA LAVIZZO-MOUREY is president and CEO of the Robert Wood Johnson Foundation (RWJF), the nation's largest philanthropy devoted exclusively to improving health and health care for all Americans. She joined RWJF in 2001 as senior vice president and director of the health care group. Previously, at the University of Pennsylvania, she was the Sylvan Eisman professor of medicine and health-care systems and director of Pennsylvania's Institute on Aging. Lavizzo-Mourey holds an M.D. from Harvard Medical School and an M.B.A. from the Wharton School at the University of Pennsylvania. She completed her residency in internal medicine at Brigham and Women's Hospital, and trained in geriatrics at the University of Pennsylvania.



MICHAEL LEAVITT is the founder and chairman of Leavitt Partners, a health-care intelligence business. Previously Leavitt served as secretary of the U.S. Department of Health and Human Services (2005-2009), administrator of the Environmental Protection Agency (2003-2005) and governor of Utah (1993-2003). At the EPA, he oversaw the implementation of the most protective ground-level ozone standards in U.S. history and signed the Clean Diesel Rule, a landmark rule to clean up non-road diesel fuel. His service at HHS included implementing the Medicare Part D Prescription Drug Program and planning for a pandemic flu. A seasoned expert in public policy, global health and health system reform, Leavitt is a sought-after speaker and advisor to CEOs, governors, members of Congress and political candidates.



JONATHAN LEFF is a managing director with Warburg Pincus, where he has been a member of the HealthCare Group since 1996. Leff is responsible for the firm's investment efforts in biotechnology. Currently he is a director of Allos Therapeutics, InterMune, ReSearch Pharmaceutical Services, Sophiris Bio, Rib-X Pharmaceuticals and Talon Therapeutics. In addition, he serves on the Executive Committee of the board of the National Venture Capital Association (NVCA) and leads the NVCA's life sciences industry efforts as chairman of its Medical Innovation and Competitiveness Coalition. Leff is a board member of the Biotechnology Industry Organization as well as Friends of Cancer Research and the Spinal Muscular Atrophy Foundation. He also sits on the Board of Visitors of Columbia University Medical Center. Leff received an A.B. degree from Harvard University and an M.B.A. from Stanford University.

RENEWING OUR COMMITMENT TO THE FUTURE



HARLAN LEVINE is executive vice president of Comprehensive Health Solutions for WellPoint, Inc. He is responsible for improving access to high-quality, affordable care for the nearly 34 million members of the company's affiliated health plans. Levine leads multiple organizations that focus on improving outcomes through clinical health management and program development, member engagement initiatives and cost-of-care management strategies. He has more than 15 years of experience providing clinical health management, consultative services and program implementation across a broad range of industries. Prior to WellPoint, Levine worked for Towers Watson as national practice leader of its health management business and earlier held leadership roles in several national health-care organizations. He earned his medical degree from the University of California, San Francisco, and is board-certified in internal medicine. Levine received his bachelor's degree in biology from Harvard College.



JONATHAN LEWIN is the Martin Donner professor and chairman of the Department of Radiology and Radiological Science at Johns Hopkins University, and the radiologist-in-chief at Johns Hopkins Hospital, with secondary appointments as professor of oncology, neurosurgery and biomedical engineering. He has been a pioneer in interventional and intra-operative magnetic resonance imaging, and has published approximately 180 peer-reviewed scientific manuscripts and more than 60 chapters, reviews, commentaries and other invited papers. Lewin is an inventor on over 20 patents, and has been a leading investigator on National Institutes of Health and other federal and state grants with awards of more than \$10 million in direct costs. He is a fellow of the International Society for Magnetic Resonance in Medicine and a fellow of the American College of Radiology. Lewin has served on numerous national committees and professional society boards, editorial boards and grant review groups for foundations and for the NIH.



FREDA LEWIS-HALL is chief medical officer and executive vice president of Pfizer Inc. Previously she held senior leadership positions at Vertex, Bristol-Myers Squibb, Pharmacia and Lilly, led research projects for the National Institutes of Health, and served as vice chairperson and associate professor of the Department of Psychiatry at Howard University College of Medicine. Lewis-Hall serves on the boards of the Patient-Centered Outcomes Research Institute, the Foundation for the National Institutes of Health, Harvard Medical School Board of Fellows, Save the Children, the Society for Women's Health Research and the Institute of Medicine's Forum on Drug Discovery, Development, and Translation. She is a fellow of the New York Academy of Medicine and a distinguished fellow of the American Psychiatric Association. She earned her undergraduate degree at Johns Hopkins University and her medical degree from Howard University College of Medicine.



FRANK LICHTENBERG is the Courtney C. Brown professor of business at the Columbia University Graduate School of Business and a research associate of the National Bureau of Economic Research. He has performed numerous econometric studies of the impact of biomedical innovation on longevity and health in the United States and other nations. He has taught at Harvard University and the Ecole Polytechnique in Paris and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich and elsewhere. A frequent consultant to government agencies, Lichtenberg has served as an expert for the Federal Trade Commission, the U.S. Department of Justice and state attorneys general. He has also worked for the Congressional Budget Office and the Census Bureau and has testified before Congress. The professor received a B.A. with honors in history from the University of Chicago and an M.A. and Ph.D. in economics from the University of Pennsylvania.



JOHN LIM is CEO of the Health Sciences Authority (HSA) of Singapore. He oversees HSA's wide-ranging responsibilities for health product regulation, the national blood service and the national forensic science and forensic medicine center. He is a member of the HSA board, the regulatory advisory board of the UK Centre for Innovation in Regulatory Science, the supervisory panel of the National Environment Agency's Environmental Health Institute and the management committee of St. Andrew's Autism Center in Singapore. He is a fellow of the Singapore Academy of Medicine and adjunct associate professor at the National University of Singapore Saw Swee Hock School of Public Health. In the course of his career, he has served as administrator of the Singapore Blood Transfusion Service, special assistant to the permanent secretary for health, deputy medical director of the Institute of Mental Health and human resource director of the Ministry of Health. Lim is a medical graduate of the National University of Singapore (NUS) and holds master's degrees from NUS and Harvard University.



SUSAN LINDQUIST is a professor of biology at MIT's Whitehead Institute and an investigator of the Howard Hughes Medical Institute. Previously Lindquist served as director of the Whitehead Institute and was on the faculty of the University of Chicago. Lindquist is a pioneer in the field of protein folding. Her work has demonstrated that alternative protein conformations have profound and unexpected effects in fields as wide-ranging as human disease, evolution and biomaterials. She is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Philosophical Society and the Institute of Medicine. Her honors include the Dickson Prize in Medicine and the Genetics Society of America Medal. She is a member of the board of Johnson & Johnson and co-founder of the biotech firm FoldRx Pharmaceuticals. Lindquist received her Ph.D. in biology from Harvard University and was a postdoctoral fellow of the American Cancer Society at the University of Chicago.




GEOFF LING is program manager in the Defense Sciences Office of the Defense Advanced Research Projects Agency (DARPA). Before joining DARPA, Ling was a professor and acting chair of the Department of Neurology at the Uniformed Services University of the Health Sciences. He served more than 27 years as a U.S. Army Medical Corps officer, including combat tours to Afghanistan (2003) and Iraq (2005) and three visits to the theater to inspect brain injury treatment on behalf of the chairman of the Joint Chiefs of Staff. He has published more than 150 peer-reviewed journal articles, reviews and book chapters. A fellow of the American Academy of Neurology, Ling is a member of the American Neurological Association and the Order of Military Medical Merit. He holds a doctorate in pharmacology from Cornell University's Graduate School of Medical Sciences and an M.D. from Georgetown University.



CHRISTOPHER LOGOTHETIS is chairman of the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, where he also directs the Genitourinary Cancer Center and the Prostate Cancer Research Program. He holds the Roy M. and Phyllis Gough Huffington Distinguished Chair in Clinical Research in Urologic Oncology. On the national level, Logothetis is a member of the Board of Scientific Advisors of the National Cancer Institute and sits on the External Advisory Committee for the NCI-sponsored project to characterize the human cancer genome. He is a fervent proponent of improving the translational research environment to align clinical care with research goals, and he champions partnerships among colleagues in academic medicine, community physicians and the patient support and advocacy communities. Logothetis received his medical degree at the University of Athens (Greece) and completed internship and residency training at Cook County Hospital in Chicago. After his fellowship at the Anderson Cancer Center, he joined the faculty.



CONNIE MACK, who represented Florida in the U.S. Senate for 12 years, currently serves as chairman emeritus of the H. Lee Moffitt Cancer Center and Research Institute. He was a leader on economic and health-care issues in the Senate and was Republican Conference chairman, making him the third-ranking member of the Senate GOP leadership. In 1996, Mack was considered by Republican presidential candidate Bob Dole to be his running mate. In 1994, Campaign and Elections magazine named Mack one of the 20 most popular elected officials in America, and as a House member, he was identified by U.S. News & World Report as one of the nation's most effective "new rising political stars." Mack is a board member of American Momentum Bank, Darden Restaurants, Inc., Mutual of America Life Insurance Co. and the Melanoma Research Alliance.



FRANCOIS MAISONROUGE is a senior managing director in Evercore Partners' advisory business and has 27 years of experience in investment banking. At Evercore, Maisonrouge was involved in advising Bristol-Myers Squibb on its acquisition of Amylin and the sale of half of its interest in Amylin to AstraZeneca; Fenwal on its pending sale to Fresenius; Terumo on its acquisition of CaridianBCT; and Sanofi on its acquisition of Genzyme. Before joining Evercore, Maisonrouge was a managing director and chairman of life sciences at Credit Suisse, where he worked extensively in pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Maisonrouge was responsible for leading the firm's relationships with large health-care clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital-raising transactions. Maisonrouge has a master's degree in engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School.



MELISSA MANCHESTER is a Grammy Award-winning singer and songwriter. From the clubs of Greenwich Village and the jingles circuit, she went on to headline Carnegie Hall and Radio City Music Hall, and her compositions have been recorded by Barbra Streisand, Alison Krauss, Roberta Flack, Johnny Mathis and many others. Among her biggest hits are "Through the Eyes of Love" and "Don't Cry Out Loud." Manchester was nominated for the Grammy in 1978 and 1979, receiving best female vocalist honors in 1982. She was the first artist in Academy Awards history to have two movie themes nominated in one year: "Through the Eyes of Love" and "The Promise" in 1980. As an actor, Manchester has starred on stage in Andrew Lloyd Webber's "Song and Dance" and Stephen Sondheim's "Sweeney Todd," and she has also been featured in film and television. The celebrated singer has received the Governor's Award from the National Academy of Recording Arts and Sciences and recently won the New York Bistro Award, presented to her by the late Marvin Hamlisch.



MICHAEL MANGANIELLO, an advocate for patients and biomedical research, is a partner and co-founder of HCM Strategists, a mission-driven strategy firm that advances good policy. He provides strategic counsel to medical research clients including *FasterCures*, the Christopher and Dana Reeve Foundation (CDRF) and the New York Stem Cell Foundation. Prior to HCM, Manganiello led CDRF's government relations office, where he drafted the Christopher Reeve Paralysis Act and raised \$22.5 million for CDRF's Paralysis Resource Center. He chaired the Paralysis Task Force, which connects 50,000 paralysis advocates nationwide. Manganiello was a founding member of the Coalition for the Advancement of Medical Research, which unites more than 100 organizations in support of medical research. Manganiello has served on several boards and advisory panels, including the NIH Director's Council of Public Representatives, the National Association for Biomedical Research, the Prevent Cancer Foundation, the National Symposium on Health Care Reform and the Whitman-Walker Clinic.



CORA MARRETT is deputy director of the National Science Foundation (NSF). She has also served as NSF's acting director, acting deputy director and senior advisor. Previously, she was the foundation's assistant director for Education and Human Resources, leading the mission to achieve excellence in science, technology, engineering and mathematics (STEM) education at all levels. From 1992 to 1996, Marrett was the first assistant director for the Social, Behavioral and Economic Sciences directorate and earned NSF's Distinguished Service Award for her groundbreaking leadership. Prior to that, she was the University of Wisconsin System's senior vice president for academic affairs and served concurrently as professor of sociology at the University of Wisconsin-Madison. She is a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Marrett holds a B.A. from Virginia Union University, and an M.A. and Ph.D. from the University of Wisconsin-Madison, all in sociology.



MARK MCCLELLAN is director and a senior fellow of the Engelberg Center for Health Care Reform and the Leonard D. Schaeffer chair in health policy studies at the Brookings Institution. At the center, his work focuses on promoting high-quality, innovative and affordable health care. A doctor and economist by training, he has a distinguished record in public service and academic research. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the Food and Drug Administration, where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, the FDA's Critical Path Initiative and public-private initiatives to develop better information on the quality and cost of care. McClellan chairs the FDA's Reagan-Udall Foundation, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He previously served on the President's Council of Economic Advisers and was an associate professor of economics and medicine at Stanford University.

KATHY MEGYERY is vice president for innovation and health-care solutions at Sanofi U.S. She is responsible for developing and implementing strategies, solutions and demonstration projects that advance Sanofi's vision as a leader in health care, sustainability and innovation. Megyery joined Sanofi in 2006, working in strategy and business development. In 2009 she was appointed to the company's Canadian Executive Committee as vice president for strategy and public affairs. Prior to that, she spent 15 years with Secor Consulting, Canada's largest privately owned management consultancy. She holds an M.B.A. from McGill University and a master's degree in economics from Concordia University.

A CELEBRATION OF SCIENCE



RICHARD MERKIN is CEO and founder of the Heritage Group, which Fast Company named one of the world's "10 Most Innovative Companies" in health care for 2012. In response to the U.S. health-care crises, Merkin created the \$3 million Heritage Health Prize for predictive modeling to save more than \$30 billion in avoidable hospitalizations. As a board member and core contributor to the X PRIZE Foundation, he advances private-sector involvement in such transformative issues as health care and education. In health care, he established the Richard Merkin Foundation for stem cell research at the Broad Institute at Harvard, the Richard Merkin Initiative at the Johns Hopkins Brain Sciences Institute and The Richard Merkin Foundation for Neural Regeneration at UCLA. In education, his work resulted in the 2006 opening of the Richard Merkin Middle School to bring first-rate education to an underserved area of Los Angeles. A board member for *FasterCures*, Merkin was named Healthcare CEO of the Year for 2011 by the Los Angeles Business Journal.



MICHAEL MILKEN has been at the forefront of a wide range of initiatives that have influenced public policy, accelerated medical research and expanded access to capital. Fortune magazine called him "The Man Who Changed Medicine" for "shaking up the medical establishment and saving lives." The inspiration behind several philanthropic initiatives worldwide, he is chairman of the Milken Institute, *FasterCures* and the Prostate Cancer Foundation, and a founder of the Melanoma Research Alliance. In 1982, Milken co-founded the Milken Family Foundation, which supports education reform and research on a wide range of life-threatening diseases. As a financier, he is often said to have revolutionized modern capital markets by expanding access to capital for more than 3,200 growing companies that created millions of jobs. He graduated with highest distinction from UC Berkeley and earned his M.B.A. at the Wharton School. Milken and his wife of 44 years, Lori, have three children and seven grandchildren. More details are at www.mikemilken.com.



LESA MITCHELL is vice president of innovation and networks at the Ewing Marion Kauffman Foundation. Her responsibilities include identification of programmatic and policy levers that can accelerate innovation and support networks that enable the growth of companies. Mitchell was instrumental in the founding of the Kauffman Innovation Network/iBridge Network, the Translational Medicine Conferences in the United States and Europe, and the National Academies-based University-Industry Partnership. She also is a leader in the replication of innovator-based commercialization and mentor programs across the United States. Mitchell recently served on the board of Denmark's Gazelle Growth program and currently is chairwoman of the Kauffman FastTrac board. She is an advisory board member of the National Science Foundation i-Corp program and of Modern Meadow Inc. Prior to joining Kauffman, Mitchell spent 20 years in global executive roles at Aventis and Quintiles and was an entrepreneur focused on the global management of electronic clinical trials.

RENEWING OUR COMMITMENT TO THE FUTURE



GEOFFREY MOORE is senior advisor to Michael Milken and senior vice president, communications, at Knowledge Universe. He also provides communications counsel to the Milken Institute, *FasterCures*, the Prostate Cancer Foundation and related organizations. He is the author of "A Call to Action," a history of the Prostate Cancer Foundation and Michael Milken's unique role in global philanthropy. Previously, Moore was a senior vice president at Dow Jones, publisher of The Wall Street Journal. He served for 22 years in communications management and executive speechwriting positions for IBM in the U.S. and Japan. Earlier, he was an assistant to New York Gov. Nelson Rockefeller, press secretary to U.S. Senate Minority Leader Hugh Scott and director of public information for the U.S. Equal Employment Opportunity Commission. His opinion articles have been published in The New York Times and other major publications. He is a graduate of the University of Pennsylvania.



LORELEI MUCCI is an associate professor of epidemiology at the Harvard School of Public Health, and she co-leads the Cancer Epidemiology program at the Dana-Farber/Harvard Cancer Center. She has more than 10 years of research and teaching experience in cancer epidemiology, with a focus on prostate cancer. As a primary or co-investigator on several funded studies, she bridges population science and molecular biology to look across the spectrum of prostate cancer incidence, cancer mortality and somatic alterations. The overarching goals of this multidisciplinary research are to reduce mortality and suffering associated with prostate cancer and to improve overall health among men. Her work puts her in collaboration with a renowned group of prostate cancer investigators and clinicians from around the world on a number of groundbreaking studies including the Nordic Twin Study of Cancer (NorTwinCan), the Prostate Cancer Patho-epidemiology Collaboration (PC)2, and Steps for Prostate Cancer Health and Survival (SPaRTACuS), a walking intervention study among men with prostate cancer.



TREVOR MUNDEL is president of the Gates Foundation's Global Health Program. The program harnesses innovations in science and technology to fight diseases such as HIV/AIDS, tuberculosis and malaria - problems that have a major impact in developing countries but receive inadequate attention and funding. Mundel oversees the program's work, leading research and development efforts toward solutions that include vaccines, drugs and diagnostics. Mundel joined the foundation in 2011. He earned his bachelor's and medical degrees at the University of the Witwatersrand in South Africa. He also studied mathematics, logic and philosophy at Balliol College, University of Oxford, as a Rhodes Scholar, and earned his Ph.D. in mathematics at the University of Chicago.



BERNARD MUNOS is the founder and "chief apostle" of breakthrough innovation at InnoThink, a consultancy that focuses on pharmaceutical innovation—specifically, where it comes from and how to get more of it. He has worked as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research has been published in *Nature* and *Science*, and he was recently profiled by *Forbes* magazine. This year, the industry newsletter *FiercePharma* named him one of the 25 most influential people in biopharma today. Munos received his M.B.A. from Stanford University, and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He advises companies, publicly funded research organizations and disease foundations on how to become better innovators.



WILLIAM NELSON is the Marion I. Knott professor of oncology and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of urology, pharmacology, medicine, pathology and radiation oncology at the Johns Hopkins University School of Medicine, with a joint appointment in environmental health sciences at the Johns Hopkins University Bloomberg School of Public Health. In addition to his administrative duties, he directs a research laboratory focused on discovering new strategies for prostate cancer treatment and prevention. The laboratory discovered the most common acquired genome change in cancer cells, a finding that has led to new approaches to prostate cancer detection, diagnosis, screening and prevention. Nelson completed M.D. and Ph.D. training, earning honors for research and clinical excellence, and then pursued internal medicine residency training and medical oncology fellowship training, all at Johns Hopkins Hospital.



STEVIE NICKS is the winner of multiple Grammy Awards and a Rock 'n Roll Hall of Fame inductee. Her extraordinary career as a solo artist, songwriter, live performer and member of Fleetwood Mac is legendary. Fleetwood Mac's "Rumours" is one of the best-selling albums of all time. Nicks penned such Fleetwood Mac classics as "Landslide," "Dreams," "Gold Dust Woman" and "Rhiannon." The five-time platinum album "Bella Donna" marked the debut of her solo career, which has produced such unforgettable singles as "Edge of Seventeen," "Leather and Lace" and "Stand Back." Nicks' new CD "In Your Dreams" debuted at No. 6 on the Billboard Top 200 Album Chart and has received glowing reviews. *Us Weekly* declared it the best album of the artist's four-decade career. Nicks is currently on her 2012 summer tour.

RENEWING OUR COMMITMENT TO THE FUTURE



JOHN O'HURLEY won a Screen Actors Guild Award for his portrayal of the iconic J. Peterman on "Seinfeld," which has become the top-rated syndicated television show in the world. He hosted the popular game shows "Family Feud" and "To Tell The Truth" and is the perennial host of the "National Dog Show" on Thanksgiving Day. O'Hurley was the ultimate champion on the first season of the runaway hit "Dancing With the Stars." A New York Times-bestselling author with two titles to his credit, he is also a Billboard chart-topping composer in the classical alternative genre, with more than 20 compositions. O'Hurley received the Ellis Island Medal of Honor in 2011 for his philanthropic efforts with his many charities. He co-founded the waste-to-energy company Energy-Inc. and is a partner in the original J. Peterman Co., the clothing catalog company on which his "Seinfeld" character was based.



PAUL PASQUINA is a colonel in the Medical Corps of the U.S. Army, chief of the Department of Orthopaedics and Rehabilitation at Walter Reed National Military Medical Center, and the director of the Center for Rehabilitation Sciences Research at the Uniformed Services University of the Health Sciences (USUHS). He is the specialty consultant to the Army Surgeon General for Physical Medicine & Rehabilitation (PM&R) and a secretarial appointee on the Department of Veterans Affairs Advisory Committee for Prosthetics and Special Disabilities Programs. Pasquina has authored multiple book chapters, journal articles and policy papers. He has served as the PM&R Residency Program director and medical advisor to the North Atlantic Regional Medical Command for quality health care. He has received multiple military awards, as well as awards for teaching and mentorship. He is a graduate of the United States Military Academy at West Point and USUHS.



NANCY PELOSI is the Democratic leader of the House of Representatives and the speaker of the House from 2007 to 2011. She is the first woman in U.S. history to lead a major political party in Congress, having initially served as House Democratic leader from 2003 to 2007. Pelosi has represented California's 8th District (San Francisco) for 25 years. She brings to her leadership position a distinguished record of legislative accomplishment. She led the Congress in passing historic health insurance reform, key investments in college aid, clean energy and innovation, and initiatives to help small businesses and veterans. From a strong family tradition of public service in Baltimore, Pelosi has been a powerful voice for civil rights and human rights for decades around the world.



ERIC PERAKSLIS is chief information officer and chief scientist (informatics) at the U.S. Food and Drug Administration. Earlier, Perakslis was senior vice president of R&D information technology at Johnson & Johnson Pharmaceuticals. He began his professional career with the Army Corps of Engineers. Perakslis' research interests are enterprise knowledge management, patient stratification, health-care IT and translational informatics. He is a late-stage kidney cancer survivor and patient advocate. Perakslis has served as chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as chief information officer of the King Hussein Institute for Biotechnology and Cancer in Jordan. He has worked with the Lance Armstrong Foundation, the Kidney Cancer Association, the Scientist Survivor program of the American Association for Cancer Research, OneMind4Research and several other nonprofit organizations. Perakslis has a Ph.D. in chemical and biochemical engineering from Drexel University and B.S.ChE and M.S. degrees in chemical engineering.



RODERIC PETTIGREW is the first director of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health. Prior to that appointment, he was professor of radiology at Emory University and bioengineering at the Georgia Institute of Technology. Pettigrew is known for his pioneering work at Emory involving four-dimensional cardiovascular imaging using magnetic resonance, or MRI. Pettigrew's awards include membership in Phi Beta Kappa, the Bennie (Benjamin E. Mays) Award for Achievement and most distinguished alumnus of the University of Miami in 1990. He has been honored with the Association of Black Cardiologists Nickens Award, the Distinguished Achievement Award of the Biomedical Engineering Society and the Distinguished Service Award of the National Medical Association. He was elected to the Institute of Medicine and the National Academy of Engineering. Pettigrew received a B.S. from Morehouse College, an M.S. from Rensselaer Polytechnic and a Ph.D. from MIT. Subsequently, he earned his M.D. at the University of Miami.



TOMAS PHILIPSON is the Daniel Levin Professor of Public Policy Studies in the Irving B. Harris Graduate School of Public Policy Studies at the University of Chicago. A senior fellow of the Milken Institute, he is also founding partner of Precision Health Economics. Previously he was a visiting faculty member at Yale University and a visiting fellow at the World Bank. Philipson, a senior health-care advisor for Sen. John McCain's 2008 presidential campaign, served as senior economic advisor to the head of the FDA and later to the head of the Centers for Medicare and Medicaid Services. The two-time winner of the Kenneth Arrow Award of the International Health Economics Association, Philipson is a co-editor of the journal *Forums for Health Economics & Policy* and sits on the editorial board of *Health Economics* and *The European Journal of Health Economics*. He holds a bachelor's degree from Sweden's Uppsala University and an M.A. and Ph.D. in economics from the Wharton School of the University of Pennsylvania.



ELIZABETH PLATZ is a professor in the Bloomberg School of Public Health at Johns Hopkins University and co-director of the Sidney Kimmel Comprehensive Cancer Center's Cancer Prevention and Control Program. Her research on prostate and colon cancers sits at the interface between epidemiology and basic science. She studies the association of genetic and epigenetic factors as well as circulating markers of androgenicity, inflammation and oxidation with prostate cancer. For colorectal neoplasia, her work focuses on the metabolic syndrome, growth factors and inflammation as sequelae of adiposity. Platz also studies the role of diet and lifestyle in relation to these and other men's health concerns. She has a long-standing interest in uncovering explanations for the higher rate of prostate cancer in African-American men compared to white men. Platz conducts her work with an eye toward identifying strategies to prevent the development or progression of cancer. These goals have led to her recent interest in the possible benefits of drugs for other indications, including statin drugs.



NATHAN PRICE is an associate professor at the Institute for Systems Biology in Seattle. A recipient of numerous awards, Price has won the Howard Temin Pathway to Independence Award in Cancer Research from the National Institutes of Health, a National Science Foundation CAREER Award and a Young Investigator Award from the Roy J. Carver Charitable Trust. He was named one of the inaugural "Tomorrow's PIs" by the journal Genome Technology and most recently was recognized as a Camille Dreyfus Teacher-Scholar. Price served on the National Academies-Institute of Medicine committee to review Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials and on the Scientific Advisory Board of TetraVitae Bioscience, Inc. He is an associate editor of BMC Systems Biology, Industrial Biotechnology and Biotechnology Journal as well as a deputy editor-in-chief of PLoS Computational Biology. Price is also a member of the Board of Directors and Scientific Advisory Board of the P4 Medicine Institute.



THOMAS PRISELAC has served as president and CEO of the Cedars-Sinai Health System since 1994 and has been associated with the organization since 1979. Priselac has served the community and health-care field in a variety of ways during his tenure with Cedars-Sinai. He is a past chair of the American Hospital Association board, past chair of the Association of American Medical Colleges and past chair of the California Hospital Association. He served on the Blue Cross of California board and subsequently became a founding member of the California Healthcare Foundation board after the conversion of Blue Cross of California to Wellpoint. The holder of the Warschaw/Law endowed chair in healthcare leadership at Cedars-Sinai Medical Center, Priselac also serves as an adjunct professor at the School of Public Health at the University of California, Los Angeles, and is an author and frequent speaker on a variety of contemporary issues in health care.

A CELEBRATION OF SCIENCE



JONATHAN PRUDEN is a retired captain of the U.S. Army. While serving in Iraq in 2003, Pruden's body absorbed 173 pieces of shrapnel and one bullet during a roadside bomb attack. After enduring nearly 20 surgeries in seven different hospitals to save his right leg, he made the difficult decision to amputate. Pruden became involved in the Wounded Warrior Project early on and now serves as the regional director for the Southeast and a peer mentor trainer. He also volunteers at the VA, serves on the advisory board of the Florida Office of Disability and Health, the steering committee of the VA's Rehabilitation Outcomes Research Center, and the Florida Disability Taskforce. On four separate occasions he testified before the U.S. Senate and House about care for wounded warriors returning from combat. He is regularly asked to speak to groups about his experiences and the challenges facing this generation of wounded warriors. Pruden has a master's degree in political science from the University of Florida.



CARMEN PULIAFITO is dean of the Keck School of Medicine of the University of Southern California, a position he has held since 2007. He continues to lead the transformation of the Keck School into one of the nation's preeminent research-intensive medical schools. Puliafito is a renowned ophthalmologist, widely recognized for his innovative advances in treatment, including his co-invention of optical coherence tomography (OCT), which revolutionized laser surgery. In addition to his responsibilities as dean, he is an active clinician at USC's Doheny Eye Institute and serves as the current editor of *Ophthalmic Surgery, Lasers and Imaging*. From 2001 to 2007, Puliafito served as chair of the Department of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. Prior to his work at Bascom Palmer, he served as founding director of the New England Eye Center and chair of the Department of Ophthalmology at Tufts University (1991 to 2001). A graduate of Harvard College and Harvard Medical School, Puliafito also earned an M.B.A. from the Wharton School of the University of Pennsylvania.



DENNIS PURCELL has been the senior managing director of Aisling Capital since 2000. The fund has \$1.7 billion of assets under management. Before joining Aisling, Purcell was managing director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for over five years. While at Hambrecht & Quist, he supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Purcell is a director of Paratek Pharmaceuticals and Xanodyne Pharmaceuticals. Previously he served as a director of Aton Pharmaceuticals, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories and Valentis Inc. He has been a member of the Advisory Council at Harvard Medical School and the board of the Biotechnology Industry Association. Purcell received his M.B.A. from Harvard University and his B.S. in accounting from the University of Delaware.

RENEWING OUR COMMITMENT TO THE FUTURE



JOHN REED is CEO of Sanford-Burnham Medical Research Institute, with more than 1,200 employees and operations in San Diego and Santa Barbara, Calif., and in Orlando, Fla. Reed's research contributions encompass a broad range of therapeutic areas, including oncology, autoimmunity/inflammation, infectious diseases and diabetes. He is a pioneer in delineating the fundamental mechanisms that regulate programmed cell death ("apoptosis"), a process by which cells in the body "commit suicide" through activation of a genetically controlled program. Reed is author of over 800 peer-reviewed scientific articles and more than 50 book chapters. He is the recipient of numerous awards for his research accomplishments, and has been awarded more than 100 research grants by government and non-government funding agencies. He serves or has served as an advisor and consultant to numerous biotechnology and pharmaceutical companies, and on the boards of several public biopharmaceutical companies.



DANIEL REICH directs the Translational Neuroradiology Unit of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Research in his lab focuses on the use of advanced MRI techniques to understand the sources of disability in multiple sclerosis. He is particularly interested in noninvasive imaging modalities to dissect biological mechanisms of tissue damage. Reich has authored more than 50 peer-reviewed publications and 100 scientific abstracts and has presented many invited lectures, both nationally and internationally. He is actively involved in training junior scientists and physicians. Trainees in his lab include postdoctoral and clinical fellows, graduate and medical students, and high school summer students. Reich earned his M.D. at Cornell University and his Ph.D. in neurophysiology from the Rockefeller University. He holds an undergraduate degree in mathematics and physics from Yale University.



HARRY REID is the majority leader in the U.S. Senate and the senior senator from Nevada. Born in the small rural mining town of Searchlight, Reid graduated from Utah State University in 1961 and went on to receive a law degree from George Washington University. After completing law school, Harry served as the city attorney in Henderson, and then as an assemblyman in the Nevada State Assembly in 1968, at age 28. In 1970, he became the youngest lieutenant governor in Nevada history and was later appointed chairman of the Nevada Gaming Commission, where for five years he fought to clean up Nevada's gaming industry. Reid served two terms in the U.S. House of Representatives. He was elected to the Senate in 1986, and re-elected in 1992, 1998, 2004 and 2010. Reid served as the chairman or senior Democratic member on several important committees and subcommittees.


A CELEBRATION OF SCIENCE



NEIL RISCH is the Lamond Family Foundation Distinguished Professor in Human Genetics, director of the Institute for Human Genetics and professor and previous co-chair of the Department of Epidemiology and Biostatistics at the University of California, San Francisco. He is also interim co-director of the new Institute for Computational Health Sciences. For the past 15 years, he has also been an adjunct investigator at the Kaiser Permanente Northern California Division of Research. Risch's research area is genetic epidemiology and statistical genetics. He has developed novel methods for discovering and characterizing genetic variants underlying disease predisposition. His research also focuses on population genetics, particularly how variation is distributed in humans. Risch is a member of the Institute of Medicine, an elected fellow of the California Academy of Sciences, a fellow of the American Association for the Advancement of Science, a director of the American Society of Human Genetics and a recipient of the Curt Stern Award from the American Society of Human Genetics.



SALLY ROCKEY is the deputy director for extramural research at the National Institutes of Health (NIH). She oversees the development and implementation of policies governing biomedical research supported by NIH across the country and around the world. In 1986, she joined the U.S. Department of Agriculture's extramural research arm, where she quickly rose to the post of deputy administrator. In 2002, she became chief information officer, aligning information technologies with the department's goals. In 2005, Rockey was appointed to her current position at the NIH. Rockey is a frequent public speaker, giving presentations on extramural research priorities and policies, grantsmanship, the competitive peer-review process, scientific integrity and IT. She received her Ph.D. in entomology from Ohio State University and has spent the majority of her career in the areas of research administration and information technology. She leads or is active on a number of federal committees related to science, federal research assistance and electronic government.



STEVEN ROSEN is the Genevieve Teuton professor of medicine at Northwestern University's Feinberg School of Medicine. He has directed the Robert H. Lurie Comprehensive Cancer Center since 1989. Under Rosen's leadership, the cancer center has built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center has been continuously funded by the National Cancer Institute since 1993, and it attained comprehensive status in 1997. He also maintains an active research laboratory that studies hormone receptors, biologic therapies and molecular mechanisms of signal transduction pathways. The laboratory's findings on the anti-cancer potential of nucleoside analogs have progressed to early-phase clinical trials of these agents.



STEVEN ROSENBERG is chief of surgery at the National Cancer Institute and a professor of surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. As the developer of the first effective immunotherapies and gene therapies for advanced cancer, Rosenberg has produced studies of cell transfer immunotherapy that have resulted in durable, complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans, and his recent studies of the adoptive transfer of genetically modified lymphocytes resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. After completing his residency in surgery in 1974, Rosenberg became chief of surgery at the NCI, a position he still holds. He received his B.A. and M.D. at Johns Hopkins University and a Ph.D. in biophysics at Harvard University.



JONATHAN ROTHBERG is the founder and CEO of Ion Torrent. He is best known for inventing high-speed, massively parallel DNA sequencing, also known as next-generation sequencing. He founded 454 Life Sciences in 1999, bringing to market the first new method for sequencing genomes since Sanger and Gilbert won the Nobel Prize in 1980. In 2007 he sequenced Nobel laureate James Watson's genome, the first individual or personal genome. That same year, Rothberg founded Ion Torrent, inventing a new sequencing technology that directly translated the language of chemistry into the binary language of computers, all on a novel semiconductor chip. The Ion Personal Genome Machine is now the fastest-selling sequencer in the world, and the Ion Proton sequencer, launching this quarter, is designed to break the \$1,000 genome barrier, making human genome sequencing a routine part of medicine. Life Technologies Acquired Ion Torrent in 2010. Rothberg is the winner of the Connecticut Medal of Technology, a member of the National Academy of Engineering and a life trustee of Carnegie Mellon University.



PAUL ROTHMAN is the dean of the medical faculty and vice president for medicine of the Johns Hopkins University as well as CEO of Johns Hopkins Medicine. He oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, Rothman came to Hopkins in July 2012 after serving as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan. Previously, he was head of internal medicine at Iowa as well as vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at the Columbia University College of Physicians and Surgeons. During his tenure at Iowa, Rothman stabilized the medical college's finances and initiated an overhaul of the curriculum. At Columbia, he built new clinical programs, expanded the faculty and increased clinical revenue and research funding 15-fold. A graduate of MIT, Rothman earned his medical degree from Yale University.



CHARLES SAWYERS is an investigator at the Howard Hughes Medical Institute and chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center. Sawyers' studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia, in collaboration with Brian Druker and Novartis, led to the development of the ABL kinase inhibitor imatinib as primary therapy for CML. This was followed by his discovery that BCR-ABL mutations confer imatinib resistance, and development of the second generation ABL kinase inhibitor dasatinib, in collaboration with Bristol-Myers Squibb. Sawyers' work in prostate cancer defined upregulation of androgen receptor signaling as the primary mechanism of resistance to hormone therapy, resulting in the discovery of the antiandrogen enzalutamide (formerly MDV3100) in collaboration with Michael Jung, which prolongs survival in men with metastatic prostate cancer. Sawyers is a member of the National Academy of Sciences and the Institute of Medicine and co-recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award.



HOWARD SCHER is chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center and a professor of medicine at the Weill Cornell Medical College. An internationally recognized investigator, Scher has helped elucidate key molecular and genetic features of prostate cancer and has translated these insights into the evaluation of novel targeted agents in the clinic. Most recently, he led the clinical development of enzalutamide (MDV3100), an androgen-receptor signaling inhibitor targeting a key driver of prostate cancer growth. His work also focuses on developing noninvasive methods of determining whether targeted therapies are working. Scher is a member of the Prostate Cancer Clinical Trials Working Group and led an international effort to standardize the design and analysis of phase II trials. He is also principal investigator of the NIH-supported Specialized Program of Research Excellence (SPORE) in Prostate Cancer and the Prostate Cancer Clinical Trials Consortium, a research collaborative funded by the Department of Defense and the Prostate Cancer Foundation.



JAY SCHNITZER is the director of the Defense Sciences Office at the Defense Advanced Research Projects Agency (DARPA). His research focus includes the interface between health-care simulation and medical disaster preparedness - a logical combination of his engineering background and medicine field experience in disasters. As surgical team leader for one of the National Disaster Medical System's surgical response teams, Schnitzer was deployed to New York City on 9/11 and Bam, Iran, after the 2003 earthquake. Previously, Schnitzer was chief medical officer and senior vice president at Boston Scientific Corp. He completed his residency training program in general surgery at the Brigham and Women's Hospital, spending one year performing trauma surgery in the Gaza Strip. He also performed a fellowship in pediatric surgery at Children's Hospital, Boston. Schnitzer received a B.S. in chemical engineering from Worcester Polytechnic Institute in Worcester, Mass., a Ph.D. in chemical engineering from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School.



ALLAN SCHWEITZER is executive managing director at Beach Point Capital Management. Schweitzer has been in the investment industry for 19 years, most recently as chief investment officer and senior portfolio manager at Post Advisory Group, where he specialized in high-yield securities. Prior to Post, Schweitzer was a senior high-yield analyst at Trust Company of the West (TCW), focusing on the health-care, media and telecommunications industries. Before joining TCW, he was an emerging-market corporate credit analyst at Putnam Investments, where he also designed global fixed-income risk models. Schweitzer received a B.A. in business administration from Washington University and an M.B.A. with a concentration in analytical finance and international economics from the University of Chicago. He currently serves on the boards of Bet Tzedek and *FasterCures*.



JOEL SELIGMAN, a leading expert in securities law, is president of the University of Rochester. He was dean of the Washington University School of Law and the University of Arizona College of Law, and a professor at the law schools of the University of Michigan, George Washington University and Northeastern University. Seligman co-authored the 11-volume "Securities Regulation," the leading treatise in the field, and wrote "The Transformation of Wall Street: A History of the Securities and Exchange Commission and Modern Corporate Finance." Seligman has authored or co-authored 20 books and more than 40 articles on securities and corporate law. He serves on the board of the Financial Industry Regulatory Authority and is a former board member of the National Association of Securities Dealers. He has also chaired the Securities and Exchange Commission's Advisory Committee on Market Information. Seligman earned his bachelor's degree from the University of California, Los Angeles, and his law degree from Harvard Law School.



VICKI SEYFERT-MARGOLIS is senior advisor for science innovation and policy in the FDA Commissioner's Office, focusing on innovation, regulatory science, personalized medicine, scientific computing and health informatics. Previously, she was chief scientific officer at the Immune Tolerance Network (ITN), a research consortium seeking treatments for immune system diseases. At ITN, she oversaw the development of 20 laboratory facilities and the design and execution of biomarker discovery studies for more than 25 Phase II clinical trials. In her biomarker efforts, she established construction of a primer library of 1,000 genes that may be involved in immunologic tolerance and co-discovered genes that may mark kidney transplant tolerance. Seyfert-Margolis was also an adjunct associate professor at the University of California, San Francisco. Prior to academia, she directed the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases. Seyfert-Margolis earned a Ph.D. in immunology at the University of Pennsylvania's school of medicine.



ELLEN SIGAL is chair and founder of Friends of Cancer Research (Friends), a think tank and advocacy organization that develops partnerships and promotes policies that will get treatments and therapies to patients in the safest and quickest way possible. Working with federal health agencies, congressional leadership, academic research centers and private industry, Friends creates innovative educational, policy and scientific approaches to improve health outcomes and cancer care. Sigal holds leadership positions with a broad range of advocacy, public policy and health organizations. Her posts include vice chair of the board of the Reagan-Udall Foundation for the Food and Drug Administration and chair of the Public/Private Partnerships Committee of the board of the Foundation for the National Institutes of Health. She is also a governor of the Patient-Centered Outcomes Research Institute board.



GREG SIMON is CEO of Greg Simon, Inc. He has held senior positions in Congress and the White House, been a senior strategy consultant to technology CEOs and was the founding president of *FasterCures*. Most recently, Simon was senior vice president for patient engagement and head of worldwide policy for Pfizer, Inc. At *FasterCures*, he led efforts to reform public policy to bring more vital medicines more quickly to doctors and patients. Prior to that, his firm, Simon Strategies, advised major international companies such as Sony, Cisco, Motorola and AOL. Simon was chief domestic policy advisor to Vice President Al Gore from 1993 to 1997. He represented Gore on the National Economic Council and oversaw key initiatives regarding the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration. The journal *Nature Medicine* named him one of "Ten People to Watch" in health policy, and he has received the Genetic Alliance's Art of Advocacy award. Simon earned his law degree at the University of Washington and his B.A. from the University of Arkansas.



MARK SIMON is an advisor and co-founder of Torrey Partners, a boutique advisory firm that assists life science companies on strategy, business development, licensing, financing alternatives, and asset monetizations/divestitures. From 1984 to 2005, Simon was involved in some 175 transactions raising about \$30 billion for life science companies. From 2002 to 2005, he was a managing director and head of Investment Banking Life Sciences at Citigroup. From 1998 to 2002, he was head of Investment Banking Life Sciences at Robertson Stephens, leading a team that conducted an in-depth pipeline review on 82 pre-POC projects for a major pharmaceutical company. During his Robertson tenure, Simon raised 45 percent of total biotechnology dollars and managed and co-managed 20 percent of all deals from 1999 to 2001. From 1989 to 1998 at Robertson, Simon was a senior research analyst covering the biotech industry and was a three-time Wall Street Journal All-Star Analyst. He holds a B.A. from Columbia College and an M.B.A. from Harvard Business School.

RENEWING OUR COMMITMENT TO THE FUTURE



JONATHAN SIMONS is the president, CEO and David H. Koch Chair of the Prostate Cancer Foundation, a position he has held since 2007. An internationally recognized prostate cancer oncologist, physician-scientist and biomedical inventor, he also served as interim chief science officer of the Melanoma Research Alliance during its launch by *FasterCures* in 2008. In 2000, Simons was recruited from the Johns Hopkins Cancer Center by Georgia Gov. Roy Barnes and the Woodruff Foundation of Atlanta to be the founding director of the Winship Cancer Institute at Emory University. Simons launched the first NCI Cancer Nanotechnology Centers at Emory and Georgia Tech in 2004. He is a graduate of Princeton University and the Johns Hopkins University School of Medicine, and did postgraduate fellowships at Cambridge University and Harvard Medical School.



ERIC SMALL is professor of medicine and urology and chief of the Division of Hematology and Oncology at the University of California, San Francisco. He is also deputy director and director of clinical sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. Small has contributed significantly to the understanding of advanced prostate cancer, with themes that include the transition from hormone-sensitive to castration-resistant disease, the development of androgen receptor directed therapies, and immunotherapy. He was directly involved in FDA approval for melanoma of three agents relevant to prostate cancer: sipuleucel-T, abiraterone and ipilimumab. He is principal investigator of the West Coast Prostate Cancer Dream Team Consortium awarded by the Prostate Cancer Foundation, Stand Up to Cancer and the American Association for Cancer Research. Small has served on the National Cancer Institute Prostate Cancer Progress Review Group and was the Scientific Program Committee chairman of the American Society of Clinical Oncology.



SUSAN SOLOMON is a co-founder and CEO of the New York Stem Cell Foundation. She is also the chair and a founding member of New Yorkers for the Advancement of Medical Research and has served on the board of the Juvenile Diabetes Research Foundation in New York City. An attorney, Solomon practiced law with Debevoise & Plimpton before beginning a 25-year career in new media, entertainment and investment banking. During this time, she served as the founding CEO of Sotheby's.com and as president and CEO of Sony Worldwide Networks.

A CELEBRATION OF SCIENCE



HOWARD SOULE is executive vice president and chief science officer at the Prostate Cancer Foundation (PCF) and a senior fellow at the Milken Institute. He previously served as managing director of the Knowledge Universe Health and Wellness Group, an investment firm focused on companies in the areas of disease prevention and treatment. Soule's first stint as executive vice president and chief science officer at PCF was from 1997 to 2004. He was responsible for coordinating scientific and clinical research funded by the foundation, whose goal is to promote new treatments and a cure for advanced prostate cancer. He was previously a senior R&D executive at Corvas International Inc., a public biotechnology company, where he focused on innovative treatments for cardiovascular diseases. In addition, he has considerable experience in the medical diagnostic and device industries. Soule received a Ph.D. from Baylor College of Medicine and was a postdoctoral fellow at The Scripps Research Institute.



GAREN STAGLIN is an investor, philanthropist and co-founder of One Mind for Research, the goal of which is to raise \$15 billion over the next 10 years to cure brain disorders. Staglin has been a CEO and director of public and private companies, and participated in venture and leveraged buyout transactions. He serves on the UCLA Chancellor's Competitiveness Council and formerly was on the advisory boards of the Stanford Graduate School of Business and the Cambridge Judge Business School in England. Staglin, his wife and children own the Staglin Family Vineyard and adhere to the motto "Great wine for great causes." In the last 10 years, causes they have chaired and donations related to their wines have generated more than \$750 million. They founded the International Mental Health Research Organization and BringChange2Mind.org, along with One Mind for Research. Staglin holds a B.S. from UCLA and an M.B.A. from Stanford.



JANET STANFORD is a full member of the Fred Hutchinson Cancer Research Center's epidemiology program. She is the co-head of the Program in Prostate Cancer Research and a research professor of epidemiology in the School of Public Health at the University of Washington. She is co-principal investigator of the Prostate Cancer SPORE grant and co-leader of one of its major research projects. Stanford is a leader in the data-collection component of the Seattle-based Prostate Cancer Genetic Research Study and is a member of the International Consortium for Prostate Cancer Genetics. Her awards include the National Research Service Award Postdoctoral Fellowship, the Preventive Oncology Academic Award and the Special Creativity Award from the Prostate Cancer Foundation. Stanford received her bachelor's degree in nursing from Georgia State University in 1980, her master's in epidemiology from Emory in 1982 and a Ph.D. in epidemiology from Johns Hopkins in 1985.



MELISSA STEVENS is deputy executive director of *FasterCures / The Center for Accelerating Medical Solutions*. She manages the planning and implementation of the organization's programs and priorities. She also directs the organization's medical philanthropy efforts including the Philanthropy Advisory Service, designed to help foundations, philanthropists and their advisors make more impactful investments in medical research and better assess the return on philanthropy. Previously, she worked in the health sciences practice of PricewaterhouseCoopers, advising commercial and federal clients across the health-care continuum. Stevens received both her bachelor's degree in biochemistry and M.B.A. from Pennsylvania State University.



SIMON STEVENS is president of global health at UnitedHealth Group, which provides health and well-being services for 75 million people in over 50 countries. As executive vice president of UnitedHealth Group, Stevens also oversees the company's Corporate Strategy Group and leads UnitedHealth's work on U.S. health reform and innovation. He serves as chairman of both the UnitedHealth Center for Health Reform and the Optum Institute. Stevens was previously CEO of UnitedHealth's \$30 billion Medicare company, and before that was British Prime Minister Tony Blair's health adviser. He has run hospitals, primary care, and payer/health commissioning organizations on both sides of the Atlantic, and has worked in Africa and South America. He is a non-executive director of a number of international health organizations and has been a visiting professor at the London School of Economics. Stevens was educated at Oxford University, Strathclyde University and Columbia University.



HOWARD STEVENSON is Sarofim-Rock professor emeritus and former senior associate dean at Harvard Business School as well as director of publishing and chairman of the Harvard Business Publishing Co. board. Stevenson was the first Sarofim-Rock chair, devoted to the study of entrepreneurship. He was also a founder and first president of the Baupost Group, Inc., which manages investment partnerships for wealthy families. Currently he co-chairs the advisory board of Baupost LLC, a \$23 billion registered investment company, and is a director of Camp Dresser and McKee, Inc. Stevenson has authored or edited 12 books and 42 articles and authored or supervised more than 150 cases at Harvard Business School. He was a member of the National Public Radio board for seven years and served as chairman from 2008 to 2010. He is a trustee of Mount Auburn Hospital, the Boston Museum of Science and the Isabella Stewart Gardner Museum, and sits on the advisory board of the Smithsonian Astrophysical Observatory. He is a member of the governing board of Insper business school in Sao Paulo, Brazil.



BRUCE STILLMAN is president of Cold Spring Harbor Laboratory and director of its Cancer Center. A native of Australia, he joined Cold Spring Harbor Laboratory in 1979. His research focuses on how chromosomes are duplicated in cells, a process that ensures accurate inheritance of genetic material from one generation to the next. He was elected to The Royal Society, the National Academy of Sciences and the American Academy of Arts and Sciences. He received the Julian Wells Medal, the Curtin Medal, the Alfred P. Sloan Prize and the Louisa Gross Horwitz Prize. Stillman is a member of the Medical Advisory Board of the Howard Hughes Medical Institute and advises the M.I.T. Koch Institute, Princeton University's Lewis-Sigler Institute and Melbourne's Walter and Eliza Hall Institute. He currently serves on the National Cancer Institute Board of Scientific Advisors and the Board of Life Sciences of the U.S. National Research Council.



SUBRA SURESH is director of the U.S. National Science Foundation (NSF). He previously served as dean of the engineering school and the Vannevar Bush professor of engineering at the Massachusetts Institute of Technology. A mechanical engineer interested in materials science and biology, Suresh pioneered research to understand the mechanical properties of materials, and most recently tackled the biomechanics of red blood cells under the influence of diseases such as malaria. In 2006, Technology Review magazine selected Suresh's work on nanobiomechanics as one of the top 10 emerging technologies that "will have a significant impact on business, medicine or culture."



RUDOLPH TANZI is the Joseph P. and Rose F. Kennedy professor of neurology at Harvard University and director of the Genetics and Aging Research Unit at Massachusetts General Hospital. Tanzi has been investigating the genetics of neurological disease since the 1980s. His research on the role of zinc and copper in Alzheimer's disease recently led to successful clinical trials at Prana Biotechnology. Tanzi serves on dozens of editorial and scientific advisory boards, and as chair of the Cure Alzheimer's Fund Research Consortium. Tanzi was included on the list of the "Harvard 100 Most Influential Alumni" and was chosen by the Geoffrey Beene Foundation as a "Rock Star of Science." He has co-authored over 400 research articles. He co-authored "Decoding Darkness: The Search for the Genetic Causes of Alzheimer's Disease" and is currently co-authoring a book with Deepak Chopra called "Super Brain." In musical pursuits, Tanzi professionally plays keyboards, most recently with Joe Perry, and for Aerosmith's upcoming album in fall 2012.

RENEWING OUR COMMITMENT TO THE FUTURE



LAURE THIBAUD is senior vice president of communications at Sanofi. Reporting directly to CEO Chris Viehbacher, she is also a member of the Management Committee. Prior to joining Sanofi, she was executive vice president of communications and sustainable development at AXA Group from 2007 to 2009. From 1990 to 2007, Thibaud held various communications positions at GlaxoSmithKline culminating in the role of vice president of external affairs, Pharmaceuticals Europe (2004-2007, Belgium). Other roles included vice president, communications, Pharmaceuticals Europe (1999-2004, London), communications director for Glaxo Wellcome France (1995-1999, Paris) and media relations manager (1990-1995). Thibaud previously worked as a PR consultant for major international companies including Air France (based in the U.S.) and Apple International. She has a master's degree in English and philosophy from the University of Paris X Nanterre.



JOE TORRE is Major League Baseball's executive vice president for baseball operations. In 2010, he concluded his third and final season as manager of the Los Angeles Dodgers after leading the team to the NLCS in 2008 and 2009. Previously, he spent 12 seasons as manager of the New York Yankees, guiding them to the playoffs every year and winning four world championships. Torre made his managerial debut with the New York Mets in 1977, becoming the first player-manager in the majors since 1959. In addition to managerial stints with the Atlanta Braves and the St. Louis Cardinals, he also spent nearly six seasons as a television broadcaster for the California Angels. Torre ranks fifth in all-time managerial wins, and was named American League Manager of the Year in 1996 and 1998. During his 17-year playing career, he was a nine-time All-Star and the 1971 NL MVP. He is chairman of the Joe Torre Safe At Home Foundation, which develops educational programs geared to ending the cycle of domestic violence.



FRED UPTON is a congressman representing southwest Michigan and its life sciences corridor, which is home to a major research university and leading medical products manufacturers. Upton, a Republican, is chairman of the House Committee on Energy and Commerce. An advocate of policies that support job creation, economic growth and American innovation, particularly in the life sciences, he has long pushed for critical investments in biomedical research and was a leader in crafting legislation that reauthorized the National Institutes of Health in the 1990s. As chairman, Upton has championed the reauthorization of FDA user fee programs for prescription drugs and medical devices, helping U.S. manufacturers better compete and bring their life-saving products to patients faster. His bill also supports generic drugs and biosimilars, aims to prevent drug shortages and promotes treatment options for children with rare diseases. He holds a bachelor's degree from the University of Michigan.



CHRIS VAN HOLLEN has represented Maryland's 8th District in the U.S. House of Representatives since 2002. He became one of the youngest members of the Democratic leadership in 2008. In addition to serving in House leadership, Van Hollen was elected by his colleagues in 2010 to serve as the top Democrat on the House Budget Committee, where he works to advance policies that support job creation and economic growth, reduce the deficit, and put America on a path to long-term fiscal sustainability. Throughout his career, Van Hollen has been a champion of education, energy, the environment, health care and civil rights. A leader in cleaning up the Chesapeake Bay, he fought successfully to obtain a historic boost in federal funds for the Bay as part of the Farm Bill and to secure provisions in the Recovery Act that provided loan guarantees for renewable energy projects. He also played an integral role in the effort to pass comprehensive health-care reform and fought to ensure that young adults receive expanded access to health insurance.



CHRIS VARMA is CEO of Blueprint Medicines. He joined Third Rock Ventures as an entrepreneur-in-residence in 2010, bringing with him experience as an entrepreneur and investor in the pharmaceutical and biotechnology industries. Prior to Third Rock, Varma was a partner at Flagship Ventures, focusing on life science investments and serving as CEO of the portfolio company Selventa (formerly known as Genstruct). At Genstruct, Varma led a rapid turnaround by restructuring and growing the business. Before joining Flagship, he oversaw efforts spanning clinical development, business development and sales at Novartis. At the Swiss drug giant, he was a director on Tekturna, a hypertension treatment. Varma is a member of the Harvard Medical School Therapeutics Advisory Council and serves on the leadership board of the McGovern Institute for Brain Research at MIT. He holds a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology, an M.S. in management from Stanford University, and both an M.S. and B.S. in computer science from Stanford.



HAROLD VARMUS, co-recipient of the Nobel Prize for studies of the genetic basis of cancer, is director of the National Cancer Institute. He took the position in 2010 after a decade as president of Memorial Sloan-Kettering Cancer Center and six years as director of the National Institutes of Health. He is a member of the National Academy of Sciences and the Institute of Medicine, and is involved in several initiatives to promote science and health in developing countries. The author of more than 350 scientific papers and five books, he recently published the memoir "The Art and Politics of Science." Varmus was a co-chairman of President Obama's Council of Advisors on Science and Technology, and co-founder and chairman of the board of the Public Library of Science. Varmus also chaired the Scientific Board of the Gates Foundation Grand Challenges in Global Health.



CHRISTOPHER VIEHBACHER is CEO of Sanofi as well as a member of its board and Strategy Committee. He is also chairman of Genzyme. After beginning his career at PricewaterhouseCoopers, he acquired broad international experience in Europe, the U.S. and Canada with GlaxoSmithKline. In his last position, Viehbacher was president of pharmaceutical operations in North America, a member of the board and co-chairman of the Portfolio Management Board. He is the former chairman of PhRMA in the United States (December 2010–April 2012) and is the current chairman of the CEO Roundtable on Cancer, which brings together U.S. employers to develop workplace initiatives that reduce the risk of cancer, enable early diagnosis and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies. More than 120 organizations are now members, covering nearly 3 million employees. Viehbacher, who lived in France for nine years, was made a knight of the French Legion of Honor in 2003. A certified public accountant, he is a graduate of Queen's University in Ontario.



WINTER VINECKI is just 13 years old, yet her resume surpasses those of many adults. In 2008, Winter's father was diagnosed with aggressive prostate cancer and died in 2009, shortly before his 40th birthday. Winter was committed to using her passion for athletics to make sure no other family would have to endure the personal hardships that her family went through. The result is Team Winter, an organization that raises awareness and funding for prostate cancer through athletic events and fundraising opportunities. For Winter, the cause is about honoring her dad, who died from prostate cancer less than one year after his diagnosis. On a daily basis, she sacrifices playtime and other luxuries kids her age take for granted to ensure that she is doing all she can to bring an end to this all-too-common disease that affects 1 in 6 American men.



KEVIN VOLPP is a staff physician at the Philadelphia VA Medical Center, founding director of the Center for Health Incentives and Behavioral Economics at the Leonard Davis Institute of Health Economics, and a professor of medicine and health care management at the Perelman School of Medicine and the Wharton School at the University of Pennsylvania. He is also director of the NIH-funded Penn CMU Roybal P30 Center in Behavioral Economics and Health as well as a core faculty member of the Center for Health Equity Research and Promotion at the Philadelphia VA Medical Center. Volpp's research focuses on the impact of financial and organizational incentives on health outcomes. His work has been published in the *New England Journal of Medicine*, *Journal of the American Medical Association* and *Health Affairs*. He holds a bachelor's degree from Harvard University, an M.D. from the University of Pennsylvania and a Ph.D. from the Wharton School in applied economics and managerial science. Volpp completed his internal medicine residency at the Brigham and Women's Hospital.

A CELEBRATION OF SCIENCE



ANDREW VON ESCHENBACH is president of Samaritan Health Initiatives, Inc. and an adjunct professor at the University of Texas MD Anderson Cancer Center. He is also a former commissioner of the U.S. Food and Drug Administration and former director of the National Cancer Institute. During his tenure at the FDA, von Eschenbach set out to modernize the agency by improving the regulatory pathway for drugs and medical devices and fostering creative projects such as the Critical Path Initiative that brought today's tools of science to the product development process. At the NCI, he championed the acceleration and integration of the discovery-development-delivery continuum. Prior to his public service, he had a three-decade-long career as a renowned physician, surgeon, oncologist and medical executive, including executive vice president at the MD Anderson Cancer Center. In 2006 von Eschenbach was named one of Time's "100 Most Influential People," and in 2007 and 2008 he was selected as one of the "50 Most Powerful Physician Executives in Healthcare" by Modern Healthcare/Modern Physician.



GEORGE VRADENBURG is chairman of USAgainstAlzheimer's, which he co-founded, and the Geoffrey Beene Foundation-Alzheimer's Initiative, which are dedicated to public education, early diagnosis and finding a cure for the disease. Additionally, Vradenburg chairs the Phillips Collection art museum and serves as vice chairman of the Chesapeake Crescent Initiative, a public-private collaboration focused on life science, energy and security. He is also a member of the Council on Foreign Relations and the Economic Club of Washington. His "encore" vocation as an activist and philanthropist follows a distinguished career in law and media that included stints as general counsel at CBS and strategic advisor to AOL Time Warner, where he worked on policy issues involved in the development of the Internet. During his tenure at Latham & Watkins, he launched the entertainment and media practice group. Vradenburg received his B.A. from Oberlin College and his J.D. from Harvard Law.



JAMES WATSON has served the Cold Spring Harbor Laboratory since 1968 as its director, president, chancellor and now chancellor emeritus. In 1953, while at Cambridge University, he and Francis Crick successfully proposed the double helical structure for DNA. They, together with Maurice Wilkins, were awarded the Nobel Prize in Physiology or Medicine in 1962. While a professor at Harvard, Watson commenced a writing career that generated "The Molecular Biology of the Gene" and "The Double Helix." He was a driving force behind the Human Genome Project that led to his receipt of the Copley Medal in 1993. Other awards are election to the National Academy of Sciences (1962), Medal of Freedom (1977), National Medal of Science (1997), City of Philadelphia Liberty Medal (2000), Benjamin Franklin Medal (2001) and Honorary Knight of the British Empire (2002). Watson was educated at the University of Chicago, where he received a B.S. in 1947, and Indiana University, where he earned a Ph.D. in zoology in 1950.

RENEWING OUR COMMITMENT TO THE FUTURE



ANNE WHITAKER is president of Sanofi's pharmaceuticals business in North America. She is a member of the firm's Global Management, Global Operations and U.S. Regional Strategic Management committees. She oversees all operations in the region, among them diabetes, oncology, cardiovascular, U.S. medical affairs, and commercial strategy and planning. Before joining Sanofi, Whitaker was senior vice president and head of the cardiovascular, metabolic and urology business unit at GlaxoSmithKline, where she had full commercial responsibility for leading, developing and managing strategic performance. Prior to that, she was GSK's senior vice president of leadership and organization development and vice president of critical and supportive care. Whitaker is a member of the NYC Roundtable and the National Pharmaceutical Council board as well as a trustee of the Healthcare Institute of New Jersey. She holds a bachelor's degree in chemistry from the University of North Alabama.



MAX WICHA serves as a distinguished professor of oncology and a breast cancer clinician as well as founding director of the University of Michigan Comprehensive Cancer Center. He is nationally known for his breast oncology research. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor. Wicha joined the University of Michigan Medical Center in 1980. He received his medical degree from Stanford University and trained in internal medicine at the University of Chicago. He went on to the National Cancer Institute, where he trained in clinical oncology and cancer biology.



OWEN WITTE is the director of the Broad Stem Cell Research Center and a professor of microbiology and pharmacology at UCLA. He is also an investigator at the Howard Hughes Medical Institute. Witte discovered tyrosine kinase activity for the ABL gene and the demonstration of the BCR-ABL oncoproteins in human leukemias, leading to the development of kinase-targeted therapy. He discovered Bruton's tyrosine kinase, which is required for normal B-lymphocyte development, and when mutated leads to the immune deficiency X-linked agammaglobulinemia. Recent work on stem cells for epithelial cancers of the prostate defined new therapies for this disease. Witte is a member of the National Academy of Sciences and the Institute of Medicine. His honors include the Milken Foundation Award, the Rosenthal Award and the Alpert Foundation Prize. Witte received a bachelor's degree from Cornell and an M.D. from Stanford. After postdoctoral research at the Massachusetts Institute of Technology, he joined the faculty at UCLA.

A CELEBRATION OF SCIENCE



JEDD WOLCHOK works at the Memorial Sloan-Kettering Cancer Center (MSKCC) as an associate director and director of immunotherapy clinical trials for the Ludwig Center for Cancer Immunotherapy. With James Allison, Wolchok was instrumental in the clinical development leading to approval of ipilimumab for advanced melanoma. He also leads the MSKCC Immune Monitoring Facility, dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapies. In 2011, Wolchok was named director of the Cancer Vaccine Collaborative (CVC), a joint initiative between the Cancer Research Institute and the Ludwig Institute for Cancer Research. The CVC is an international clinical trials network dedicated to developing vaccines and other immunotherapies for cancer. The CVC has conducted nearly 50 early-phase clinical trials of vaccines involving more than 950 cancer patients. Wolchok received his undergraduate degree from Princeton University and M.D. and Ph.D. from New York University, where he also fulfilled his residency program.



JANET WOODCOCK is the director of the Center for Drug Evaluation and Research at the Food and Drug Administration. At the FDA, she introduced the concept of pharmaceutical risk management in 2000 as a new approach to drug safety. Since 2002, she has led the Pharmaceutical Quality for the 21st Century Initiative, an effort to modernize drug manufacturing and its regulation. In 2004, she introduced the FDA's Critical Path Initiative, designed to improve the scientific basis for medical product development. Woodcock's honors include a Presidential Rank Meritorious Executive Award, the Nathan Davis Award from the American Medical Association (1999), the Roger W. Jones Award for Executive Leadership from American University (2000) and the Public Health Leadership Award (2004) from the National Organization for Rare Disorders. She has authored over 60 publications. Woodcock holds an undergraduate degree from Bucknell University and an M.D. from Northwestern University Medical School. She has taught at Pennsylvania State University and the University of California, San Francisco.



MARY WOOLLEY is the president and CEO of Research!America, the nation's largest not-for-profit public education and advocacy alliance working to make research to improve health a higher national priority. Woolley is an elected member of the Institute of Medicine and serves on its Governing Council. She is a fellow of the American Association for the Advancement of Science and serves on the National Academy of Sciences Board on Life Sciences. Woolley has a 30-year editorial and publication history on topics related to science advocacy and research.



KEITH YAMAMOTO is vice chancellor for research, executive vice dean of the school of medicine, and professor of cellular and molecular pharmacology at the University of California, San Francisco. His research is focused on signaling and transcriptional regulation by nuclear receptors, which mediate the actions of several classes of essential hormones and cellular signals. Yamamoto has led or served on numerous national committees focused on public and scientific policy, public understanding and support of biological research, and science education. He has also chaired or served on many committees that oversee the process of peer review and the policies that govern it at the National Institutes of Health. Yamamoto is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences and the American Academy of Microbiology, and is a fellow of the American Association for the Advancement of Science.



ELIAS ZERHOUNI is president for global research and development and a member of the Executive Committee for Sanofi. Before assuming this role, Zerhouni was a scientific advisor to the company and played an instrumental role in redesigning the Sanofi R&D model to foster increased innovation through scientific networks. At Johns Hopkins University and Hospital, he was professor of radiology and biomedical engineering. He served as director of the National Institutes of Health from 2002 to 2008. In that position he oversaw the NIH's 27 institutes and centers with more than 18,000 employees and a budget of \$29.5 billion (2008). In November 2009, President Obama appointed Zerhouni as one of the first presidential science envoys. Zerhouni has founded or co-founded five startup companies, authored more than 200 publications and holds eight patents. He is a senior fellow of the Bill & Melinda Gates Foundation and a trustee of the Mayo Clinic. He is also a member of the Institute of Medicine of the U.S. National Academy of Sciences.

A CELEBRATION OF SCIENCE

ACKNOWLEDGEMENTS

FasterCures and the Milken Institute wish to thank several organizations and their staffs for invaluable assistance in planning the Celebration of Science: **The National Institutes of Health, George Washington University, The U.S. Food and Drug Administration, The National Portrait Gallery** and **The Kennedy Center for the Performing Arts**. We also thank the many nonprofit, disease-specific research organizations who helped make this event possible. These groups have a singular focus on, and a significant stake in, getting promising therapies to patients quickly and are often the engine behind innovation in disease research. Many of these organizations are part of The Research Acceleration and Innovation Network (TRAIN), a *FasterCures* program established to create opportunities for medical research innovators to discuss and tackle challenges that cut across diseases. TRAIN's participating organizations are highlighted on the following pages.


TRAIN - THE RESEARCH ACCELERATION AND INNOVATION NETWORK



TRAIN - THE RESEARCH ACCELERATION AND INNOVATION NETWORK



TRAIN - THE RESEARCH ACCELERATION AND INNOVATION NETWORK





US

PARTNERING FOR CURES

JOIN

NOVEMBER 28-30, 2012 GRAND HYATT NEW YORK

Facilitating Cross-Sector Collaborations

Be a part of medical research's most forward-thinking, outcomes-oriented, and patient-focused event.


The Partnering for Cures conference brings together leaders from all sectors of the medical research enterprise to turn promising scientific discoveries into accessible therapies.

It is where transformative ideas, best practices, and lessons learned are shared freely and amplified for greater impact.



REGISTER NOW.

www.PartneringforCures.org



The clock is ticking...

**EVERY 68 SECONDS, SOMEONE IS DIAGNOSED
WITH DIABETES.**

**EVERY 24 SECONDS, SOMEONE IS
DIAGNOSED WITH CANCER.**

**EVERY 18 SECONDS,
SOMEONE DEVELOPS
ALZHEIMER'S DISEASE.**

the list goes on...


**MORE THAN
100 MILLION AMERICANS
SUFFER FROM DISEASES FOR WHICH
THERE ARE FEW OR NO TREATMENT OPTIONS.**

**AND YET,
WHEN A SCIENTIFIC BREAKTHROUGH IS
DISCOVERED, IT COULD TAKE 15 YEARS TO
TURN IT INTO AN
ACCESSIBLE THERAPY.**

**IMAGINE
IF THIS WERE
FASTER.**

FasterCures
The Center for Accelerating Medical Solutions

OUR NAME. OUR MISSION.
www.fastercures.org




Hotels & Venues Washington, D.C.

- 1 Four Seasons Hotel**
2800 Pennsylvania Ave. NW
- 2 Mayflower Hotel**
1127 Connecticut Ave. NW
- 3 JW Marriott**
1331 Pennsylvania Ave NW

- 4 Smithsonian National
Portrait Gallery**
800 F St. NW
*Bus entrance from G Street.
Valet and Shuttle entrance from F Street.*
- 5 John F. Kennedy Center
for the Performing Arts**
Eisenhower Theater
2700 F St. NW
Self-Parking in theater lots

- 6 Cloyd Heck Marvin Center**
George Washington University
800 21st St. NW
- 7 Jack Morton Auditorium**
George Washington University
805 21st St. NW



National Institutes of Health

9000 Rockville Pike, Bethesda, MD 20892



Ruth Kirschstein Auditorium

Natcher Conference Center



Parking: Enter through NIH Gateway Drive.


- Traveling southbound on Rockville Pike, go past South Drive; NIH Gateway Drive is on the right.
- Traveling northbound on Rockville Pike, go past Center Drive and make a U-turn at South Drive; NIH Gateway Drive is on the right.



Metro: On Saturday, September 8, major stops on the Red Line will be **closed** (Union Station through Farragut North). This will cause major delays in train service and make it difficult to transfer from other lines. Please plan accordingly if you intend to take the Red Line to Medical Center Station. Alternatively, come to one of the host hotels and take a bus to NIH.



Guests being dropped off: Enter at South Drive and turn right to reach the Kiss and Ride Lot.



MILKEN INSTITUTE



2013

**GLOBAL
CONFERENCE**

APRIL 28 - MAY 1
BEVERLY HILTON
LOS ANGELES

www.globalconference.org



MILKEN INSTITUTE

1250 Fourth Street
Santa Monica, CA 90401
Phone: (310) 570-4600

E-mail: info@milkeninstitute.org
www.milkeninstitute.org

FasterCures
The Center for Accelerating Medical Solutions

1101 New York Ave. NW, Suite 620
Washington, DC 20005
Phone: (202) 336-8900

www.fastercures.org



Recycled content